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ABSTRACT
The goal of this study was to develop a biodegradable and conductive scaffold to mimic
the piezoelectric properties of bone and the architecture of the extracellular matrix. Poly(3,4ethylenedioxythiophene) (PEDOT) is a conductive polymer of great interest in tissue engineering
due to excellent electrical stability and biocompatibility. To enhance its conductivity, dopants such
as dimethyl sulfoxide (DMSO) can be added. Engineered graphene oxide (GO) can also be
introduced as oxidant to enhance conductivity and mechanical properties. PEDOT nanocomposites
were synthesized by oxidative polymerization of 3, 4-Etylenedioxythiophene monomer (EDOT)
in the presence of GO, DMSO, ferric chloride and various solvents. The reaction yield was
determined as well as morphologies and chemical composition using SEM, EDS, TEM, and XPS.
Cytocompatibility assays were performed on bone marrow stem cells (BMSCs) to assess cellular
adhesion, proliferation, and cytotoxicity. GO/DMSO-doped PEDOT nanocomposites were then
added to a 10% solution of Poly (є-caprolactone) (PCL) in chloroform and 3D nanofibrous scaffold
was subsequently produced through melt-electrowriting (MEW) 3D printing technology. In
summary, we produced a non-cytotoxic electroconductive polymer with effective dopants that was
used in the fabrication of a nanofibrous bone scaffold. This electroactive scaffold may be useful
for cellular growth, differentiation, and bone tissue formation.
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CHAPTER I

INTRODUCTION
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I.1. Introduction
The treatment of large bone fractures remains a significant challenge to the orthopaedic
surgeons worldwide. These large bone fractures can lead to significant bone loss from trauma,
infection, tumor resection, or developmental deformities. However, the overall incidence of
critical-sized bone defects is low. For instance, in one 10-year fracture registry, only 0.4% of all
fractures at a level-1 trauma center were complicated by significant bone loss.1 Typically, bone
harnesses an inherent capacity to repair itself, but its ability to bridge very large or poorly
vascularized defects remains limited.2 In such cases, the bone fractures can lead to delayed unions
or nonunions. It is estimated that there are 6 million fractures in the United States annually and of
those, 5–10% proceed to nonunion.3 The risk of nonunion is increased based on certain patient
factors such as smoking habit or diabetes and varies by location of fracture with those of the
scaphoid waist, neck of femur, and open fractures of the tibia being especially susceptible.3,4 The
tibia’s limited soft tissue coverage predisposes it to open fractures and bone extrusion in the highenergy setting. In fact, in open injuries the incidence of tibial nonunion increases to 23%.5

Current surgical strategies utilized for tibial bone defects are both complex and costly.6 There
are multiple treatment methods to promote fracture healing and in the case of operative treatments,
bone grafting is commonly utilized to help provide a scaffold to newly forming bone.4,7 As such,
the demand for bone grafts is considerable and represents the second most common tissue
transplantation procedure after blood, with over 2.2 million bone graft procedures conducted
worldwide annually.8 Commonly used bone grafting is an imperfect solution leading to undesired
affects such as donor site morbidities, risk of infections, immune rejection, and disease
transmission.7-9 Therefore, novel solutions are required to overcome the limitations of current bone
grafting approaches through tissue engineering and regenerative medicine.

Bone tissue engineering utilizes a combination of stem/progenitor cells, biocompatible
scaffolds, and bioactive stimuli to hasten bone healing without the associated drawbacks of
grafting techniques.8,10 Success of bone tissue engineering approaches depends largely on the
choice of cells, scaffold material, and the osteogenic stimulus which can be added to the cell–
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scaffold matrix, or present in the microenvironment of the healing defect.11,12 While most attention
has focused on the delivery of exogenous biochemical stimuli through the use of growth factors,
recombinant proteins or bioactive peptides; the application of biophysical cues via mechanical,
electrical, or electromagnetic stimulation offers novel alternatives for bone tissue regeneration. 12
More specifically, electrical stimulation therapy, is being evaluated for its potential to promote
stem cell adhesion, migration, proliferation, and osteogenic differentiation.11-13 To allow the direct
delivery of electrical stimulation at the cell, tissue, or organ level, electrically conductive scaffolds
have emerged as useful tools, and their potential to modulate cell behavior has been evaluated in
a wide range of cells.14,15 Such a scaffold could also mimic the piezoelectric properties of bone
and the architecture of the extracellular matrix, so they can significantly modulate stem cell
performance.16 Therefore, the ongoing development of new electroconductive scaffolds for
electrical stimulation therapy is important and could potentially be used to optimize outcomes in
bone fracture treatments. This chapter therefore focuses on bone biology and healing, bone tissue
engineering, and conductive polymers, in which the rationale of this project is discussed.

I.2. Bone Biology
The human body consists of 206 bones, each with its own unique shape and function. They
support the body structurally, protect our vital organs, and allow us to move. Bones also provide
an environment for bone marrow, where the blood cells are created, and they act as a storage area
for minerals, particularly calcium. The different types of bone in the human body can be
categorized as flat, long, short, irregular, and sesamoid.17,18 Flat bones protect internal organs and
can be found in the skull, ribs and sternum, and pelvis. These bones are flattened offering
protection while also providing large areas for muscle attachment. Long bones support weight and
facilitate movement. Long bones are longer than they are wide and are found in both the upper and
lower limbs of the body. Short bones are cubed shaped as they are about as long as they are wide.
These are located in the wrist and ankle joints and provide stability and some movement. Irregular
bones get their name from their complex shape and structure. Their complex form helps them
protect internal organs. The vertebrae of the spine and the bones of the pelvis are examples of this.
Finally, sesamoid bones are bones embedded in tendons to help protect tendons from stress and
wear. These small, round bones are found in the tendons of hands, keens, and feet.
3

Within the various bones of the body, there resides a complex composition. Firstly, there are
two types of bones: compact cortical bone and trabecular or spongy cancellous bone. Cortical bone
attributes to the hard outer layer that is dense, strong, and durable. It makes up around 80% of
adult bone mass.18 Cancellous bone consists of a network of trabecular or rod-like structures. It is
lighter, less dense, and more flexible than compact bone. The space in between the trabeculae is
occupied by hemopoietic bone marrow.74 Bone also contains inorganic mineral salts within the
matrix, nerves and blood vessels, cartilage, as well as membranes, including endosteum and
periosteum (Figure 1.1).17-19

Osteon
Periosteum
Compact bone
Vein
Artery

Bone marrow

Endosteum

Nerve

Spongy bone

Figure 1.1. Schematic of the anatomy of bone.24

Bones are not a static tissue but need to be constantly maintained and remodeled. There are
three main cell types involved in this process. The first cell type is osteoblasts. Osteoblasts are
responsible for making new bone and repairing older bone. These cells produce a protein mixture
called osteoid, which is mineralized and becomes bone.17,21 They also manufacture hormones,
including prostaglandins.21 Osteocytes are another cell type, and these cells are inactive osteoblasts
4

that have become trapped in the bone that they have created. They maintain connections to other
osteocytes and osteoblasts.17 They are important for communication within bone tissue. The final
cell type is osteoclasts. these are large cells with more than one nucleus. Their job is to break down
bone. Osteoclasts release enzymes and acids to dissolve minerals in bone and digest them through
a process called resorption.18,21 Osteoclasts help remodel injured bones and create pathways for
nerves and blood vessels to travel through.

When bone fractures, it generally heals in one of two ways. One way is through the process
termed primary bone healing. This typically occurs in situations where there is no movement
between the bone ends and they are held compressed close together.22 During this process, the
bone structure is gradually replaced by longitudinal revascularized osteons carrying
osteoprogenitor cells which differentiate into osteoblasts and produce lamellar bone on each
surface of the gap.23 This process is also termed ‘bone remodeling’ and is the same process used
for the replacement of old bone tissue by new bone tissue.

The other process for healing bone is termed secondary bone healing. Secondary bone
healing is the process where the body forms a scar tissue in response to the fracture. The fibrous
tissue accumulates and matures, making the bone ends stiffer and reducing the movement.22 This
process occurs in four phases: hematoma formation, soft callus formation, hard callus formation,
and bone remodeling (Figure 1.2). In the initial phase of fracture healing, an inflammatory
response is initiated generating a hematoma consisting of osteoclasts derived from the bone
marrow. The response causes the hematoma to coagulate in between and around the fracture ends,
and within the medulla forming a template for callus formation (Figure 1.2-A). The initial
inflammatory response involves secretion of tumor necrosis factor-α (TNF-α), interleukin-1 (IL1), IL-6, IL-11 and IL-18. These factors recruit inflammatory cells and promote angiogenesis.2,3
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A.

B.

C.

D.

Figure 1.2. Schematic representing the four phases of bone fracture healing. A) Hematoma
formation, B) Soft callus formation, C) Hard callus formation, D) Bone remodeling.24

Specific mesenchymal stem cells (MSCs) are recruited from the surrounding soft tissues,
cortex, periosteum, and bone marrow to proliferate and differentiate into osteoblast so the bone
can begin to regenerate. 3 The recruitment of MSCs determines the outcome of the next phase in
bone healing, the formation of a fibrin-rich cartilaginous callus tissue (Figure 1.2-B). Within this
tissue, endochondral formation occurs in between the fracture ends, and external to periosteal sites.
These regions are also mechanically less stable, and the cartilaginous tissue forms a soft callus
which gives the fracture a stable structure.3 In this process the superfamily of the transforming
growth factor β (TGF-β), including the bone morphogenetic proteins (BMPs), and the group of the
insulin-like growth factors (IGFs) have a direct influence on osteoblast differentiation and
activity.2,3,18
6

In order for bone regeneration to progress, the primary soft cartilaginous callus needs to be
resorbed and replaced by a hard bony callus (Figure 1.2-C). As fracture callus chondrocytes
proliferate, they become hypertrophic, and the extracellular matrix becomes calcified. A cascade
orchestrated primarily by macrophage colony-stimulating factor (M-CSF), receptor activator of
nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG) and TNF-α initiates the resorption
of this mineralized cartilage. The calcification mechanism involves the mitochondria, which
accumulate calcium-containing granules created in the hypoxic fracture environment. As the hard
callus formation progresses and the calcified cartilage is replaced with woven bone (Figure 1.3A), the callus becomes more solid and mechanically rigid. Bone formation is regulated through a
hierarchical expression of transcription factors including Runt-related transcription factor 2
(Runx2) which is an essential transcription factor for osteoblast differentiation, matrix production,
and mineralization during bone formation. Runx2 positively regulates mRNA of proteins like
osteocalcin (OCN), osteopontin (OPN), RANK-L, alkaline phosphatase (ALP), OPG, collagen
type 1 alpha 1 (Col1), matrix metalloproteinase -13 (MMP-13), and bone sialoprotein.25-26

A.

B.

Figure 1.3. Histological images of lamellar bone and woven bone.27
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Although the woven bone is a rigid structure providing biomechanical stability, it does not
fully restore the biomechanical properties of normal bone. In order to achieve this, the fracture
healing cascade initiates a second resorptive phase, this time to remodel the hard callus into a
lamellar bone structure with a central medullary cavity (Figure 1.2-D). This phase is biochemically
orchestrated by IL-1, TNF-α and BMP-2.2 The remodeling process is carried out by a balance of
hard callus resorption by osteoclasts, and lamellar bone deposition by osteoblasts (Figure 1.3-B).
For bone remodeling to be successful, an adequate blood supply and a gradual increase in
mechanical stability is crucial. As previously stated, the tibia is located in a region with limited
soft tissue coverage and vascular supply and thus when the requirements are not met or there is
unstable fixation, the healing results in an atrophic nonunion or a pseudarthrosis (Figure 1.4).

A.

B.

Figure 1.4. A) Atrophic non-union of the tibial shaft. B) Internal fixation of tibia fracture.28
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I.3. Segmental Bone Defects
A critical segmental bone defect can be simply defined as a bone void that will not fill
without intervention. In adult patients, a critical bone defect generally has circumferential loss
>50% or a length of >2 cm.7 This bone loss can result from trauma, usually in the high-energy
setting, infection, or malignancy. Few bone defects cannot be reconstructed, and several reliable
reconstruction methods exist. However, reconstruction remains an elective procedure that
demands a significant investment of time, resources, and effort by the patient and surgeon. Optimal
patient characteristics for segmental bone defect reconstruction include a reliable and wellinformed patient with a stable soft-tissue envelope, adequate nutritional status, and the absence of
tobacco use and infection.7 Many patients present with less than ideal characteristics and increase
the difficulty of successful reconstruction.

All available treatments for segmental bone defects are based upon specific molecular and
cellular mechanisms. The process of bone healing recapitulates bone development and can be
considered a form of tissue regeneration. However, despite the regenerative capacity of skeletal
tissue, this biological process sometimes fails when too much bone is lost, and fractures may heal
in unfavorable anatomical positions, show a delay in healing, or even develop pseudrthrosis or
non-unions.22 As stated, the tibia is especially susceptible to a failure in the biological healing
process because of sparse soft tissue coverage and a precarious vascular supply.

A variety of treatments are available when examining bone defects in the tibia, but those
associated with complex open fractures require a careful approach and planning. When assessing
these patients in the acute setting, the initial step is to establish whether the limb is salvageable.
Surgical techniques such as bone transport, acute limb shortening and lengthening, massive
allografts or vascularized fibular allografts, induced membrane techniques (Masquelet technique),
and bone grafting; all offer their own set of advantages and disadvantages when attempting to
salvage the injured limb.7,29 The ideal treatment should meet the requirements of providing both
mechanical and biological support to the defect. A successful bone graft contains the main key
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factors to enhance bone repair: osteoinductive biomolecules, osteoconductive scaffold, and
osteocompetent cells.

Autologous bone grafting is currently used as the gold standard for segmental defects, as it
confers complete biocompatibility while possessing osteoinductive, osteoconductive and
osteogenic healing potentials.9 Autologous bone grafting is the process by which osseous matter
is harvested from one anatomic site, usually the iliac crest, and transplanted to another site in the
same patient. This type of bone grafting can appear in the form of cancellous or cortical bone
grafts, vascularized bone grafts, bone marrow aspirates, or platelet-rich plasma (PRP)
suspensions.7 Historically, this treatment option is associated with a relatively high rate of
complications, including persistent pain and morbidity at the harvest site, infection, and substantial
blood loss. Additionally, the quality and quantity of autologous bone graft can vary significantly
based on the harvest site as well as the host factors such as aging and health status.30

Autografts

Allografts

Xenografts

Figure 1.5. The different sources for bone grafts.31
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While acting as the gold standard, a variety of bone graft substitutes have been studied and
are challenging the autologous bone graft. Allopathic bone grafts, refer to bone that is harvested
from human cadavers, sterilely processed, and transplanted to a recipient. Allografts can be
osteochondral, cortical, cancellous, and highly processed bone derivatives such as demineralized
bone matrix. Depending on the preparation process, allograft only exhibits osteoconductive
potential.7 Allografts do not include viable cells and are therefore not osteogenic. The lack of donor
site morbidity, general success of outcomes, and decreased surgical times make allograft a popular
alternative, yet high costs and risks such as viral transmission make allograft an imperfect
substitute.

A less commonly used bone graft substitutes are the xenografts. Bone xenografts are derived
from non-living bone of another species, mostly bovine. The bone is subjected to high
temperatures and require more sterile processing, which result in the lack of any osteogenic
properties. Owing to the abundance of donors, these grafts are less expensive and more readily
available. However, xenografts present multiple limitations, such as possible transmission of
bovine spongiform encephalopathy (BSE) is still potentially inherent.32 BSE is a kind of
transmissible spongiform encephalopathies (TSE), a fatal neurodegenerative disorder that can be
transmitted to humans.33 Alternatively, tissue engineering is being considered as promising
alternative for the treatment of critical segmental bone defects.

I.4. Bone Tissue Engineering
Tissue engineering and regenerative medicine requires comprehensive efforts to combine
engineering and physical sciences with life sciences. Tissue engineering is a relatively new field
that uses living cells, biocompatible materials, and suitable biochemical and physical factors, as
well as combinations thereof, to create tissue-like constructs. The ultimate goal of tissue
engineering is to assemble functional tissue constructs to repair, replace, or improve the function
of a failing tissue or organ due to disease, congenital abnormalities, or traumatic injuries.10 The
classic bone tissue engineering paradigm highlights several key players: (1) a biocompatible
scaffold that closely mimics the natural bone extracellular matrix niche, (2) osteogenic cells to lay
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down the bone tissue matrix, and (3) morphogenic signals that help to direct the cells to the
phenotypically desirable type (Figure 1.6). Research in this field continues to focus on the
advancement of three-dimensional scaffolds for bone graft substitutes to help treat complicated
bone defects and issues with delayed or nonunions. It is the hope that bone tissue engineering will
be the future treatment of choice, as it will likely eliminate many of the pitfalls of current
treatments used today.

Figure 1.6. Figure summarizing the three main components of bone tissue engineering. Biological
strategies, including competent cells, genes, growth factors and other biomolecules, bone tissue
scaffolds in which biological components can reside, and physicomechanical strategies, to provide
a stimulus for bone regeneration.8

Scaffolds for bone tissue engineering should be biocompatible and have mechanical strength
as well as a porous structure that serve as medium over which cells can adhere, proliferate and
deposit bone. Scaffolds with unique morphology and structural architecture encourage cells to
regenerate bone tissues of the extra cellular matrix (ECM). Ideally, biodegradable scaffolds
12

provide the anatomical support for the multiplying cells to repair the damaged tissue and in the
process, undergo gradual degeneration and resorb without influencing the local homeostasis. Once
implanted, they will be replaced by newly native bone and do not require a second surgery for
removal. The architecture and composition of the scaffolds should aid in attachment, proliferation,
and differentiation of the surrounding host cells into the defect area on its surface.34 A variety of
materials are being evaluated to be used as bone scaffolds and can be classified as natural or
synthetic biomaterials. Synthetic biomaterials have several advantages over the natural
biomaterials in terms of high mechanical strength, biocompatibility, biodegradability, and cost
effectiveness.34 Biomaterials including synthetic polymers, bioactive ceramics, glasses, and their
composites are of clinical interest.

To enhance a biomaterials biofunctionality in bone tissue engineering, several
osteoinductive and angiogenic growth factors are typically used. Although the world of
biomaterials has shown great promise and improvement, there has not been credible advancements
in the osteoinductive growth factors needed to enhance the biofunctionality of the biomaterials.
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is the only FDA approved growth
factor and it has shown success when used clinically for single-level anterior lumbar interbody
fusion (ALIF), for tibial nonunions, and for oral maxillofacial reconstructions.35 However,
supraphysiological dosages of BMP-2 are required to generate significant bone regeneration,
which can be associated with frequent and life-threatening side effects including cervical swelling,
tumorigenesis, postoperative inflammation and associated adverse effects such as, ectopic bone
formation, and osteoclast-mediated bone resorption. Therefore, scientist continue to search for
alternative treatments for bone regeneration, that remain osteoinductive and safe, while presenting
efficient and successful outcomes in bone regeneration.

I.5. Electrical Stimulation
Electrical stimulation is being evaluated for its potential to be applied in tissue engineering
to promote different tissue healing and regeneration. In fact, electrical current has been reported
to enhance wound healing, nerve regeneration, muscle contraction, and bone growth.36 There have
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been case reports of success using electrical stimulation as early as 1841, but the use of this method
of treatment did not progress until the 1950s.37 In 1957, Fukada and Yusuda studied the
piezoelectric effect of bone in the femurs of man and ox.38 The phenomenon termed the
“piezoelectric effect” is essentially the ability in which materials can generate an electric charge
in response to applied mechanical stress. These findings made it known that there are electrical
potentials in bone, including stress-generated potentials and bioelectric or steady-state
potentials.37,39 In a fracture, bone collagen fibers slide against each other, leading to the
accumulation of charges and the generation of a current, which opens calcium ion channels in
osteocytes, triggering a cascade of signaling pathways that help promote bone formation.40

Since the discovery of this effect, a variety of instruments have been developed to deliver
electrical field to fracture sites, each being categorized into one of three types: invasive directcurrent (DC) stimulators, noninvasive capacitive coupling (CC) stimulators, and noninvasive
inductive coupling (IC) stimulators (Figure 7).

A.

B.

C.

Figure 1.7. Schematic of the three types of electrical stimulation methods. A) Direct coupling,
B) Capacitive coupling, C) Inductive coupling.12

Direct current stimulation is an invasive procedure, which involves the surgical placement
of electrodes, with the cathode placed in the defect and the anode place in proximate soft tissue.12,37
Although bone growth has been demonstrated using currents between 5 and 100 μA, because of
the invasive nature of the procedure, direct current stimulation has the risk of infection and tissue
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reaction.12 Capacitive coupling is a non-invasive procedure that consists of electrodes placed on
top of the skin across from the defect or fracture. Bone growth has been demonstrated using
potentials of 1-10 V at frequencies 20-200 kHz, which generate electric fields of 1-100 mV/cm.12
However, this technique requires longer treatment times and increased voltage as the electrodes
are not in direct contact with bone.41 The implementation of a conductive scaffold as a substrate
can help control the voltage needed for the electrical stimulation to occur. Another non-invasive
procedure is inductive coupling, which enhances bone healing by using electromagnetic fields
generated using Helmholtz coils placed across the defect or fracture. These electromagnetic fields
are induced at right angles to the coil base by the electricity passing through them.42 The
stimulation of bone growth has been shown using electromagnetic fields of 0.01-2.0 T in strength
with electrical field of 1-100 mV/cm at the fracture site.12 Although this method remains noninvasive, the use of electromagnetic field has shown unexplained tumorigenesis when applied.
Table 1.1 summarizes these techniques in an in vivo setting.

Table 1.1. Electrical stimulation methods.12,42
Methods
Direct coupling

Description
One or multiple
surgically implanted
cathodes with one
cutaneous electrode

Advantages
Easy operation

Disadvantages
Insufficient
biocompatibility of the
electrode

Capacitive coupling

Two cutaneous
electrodes or capacitor
plates

Noninvasive
More biologically safe

High voltage between the
electrodes
Longer treatment time

Inductive coupling

Cutaneous
electromagnetic
Helmholtz coils

Mimics the natural
potential transfer in
the human body, does
not directly touch cells

Tumorigenesis in
unexpected areas

The underlying mechanisms involved in electrical stimulation are complex and remain
elusive. Many studies have observed the upregulation of mRNA levels for bone morphogenic
proteins (BMPs)-2, -3, -4, -5, -6, -7, and -8, as well as gremlin and noggin.36,43 One hypothesis is
that that electrical stimulation can stimulate calcium signaling and increase bone formation.41
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Calcium ions are found throughout the body and help regulate many important physiological
functions. The parathyroid hormone (PTH), which is affected by serum Ca2+ levels, directly alters
bone resorption by acting as a potent stimulus for osteoclasts. When PTH is released, it acts upon
adenyl cyclase which in turn regulates cyclic AMP (cAMP) and prevents the body from forming
new bone. However, increases in pressure, or the induction of electrical stimulation inhibits
membrane-associated cAMP and in turn increases cellular uptake of calcium.41 In addition, in vitro
studies have shown that in various cell models, electrical stimulation (i) induces an increase in
osteoblast differentiation, promoting the production of collagen and of the main matrix
glycoproteins osteocalcin and osteopontin; (ii) stimulates the mineralization process; and (iii) plays
an inhibitory role in the process of osteoclast differentiation and exerts a protective action against
osteolysis.44 Other studies have shown enhanced bone marrow stem cell proliferation and
osteogenic markers expression, including Runx2, osteopontin and osteocalcin, as well as the
expression of important osteogenic growth factors for the regeneration of bone, such as TGFβ1.44,45 Electrical stimulation has even shown potential in the ability to inhibit bacterial growth
through the disruption of the bacterial membrane, causing cell leakage.46 With interest rising in
electrical stimulation therapy for bone regeneration, future applications may steer toward the use
of capacitive coupling stimulators, as it offers promising results with limited drawbacks. In such
applications, an electroactive substrate or scaffold may be in the answer to facilitate electrical
stimulation for bone regeneration. To do this, a biocompatible and electroconductive material that
supports cells adhesion and growth is needed.

I.6. Conductive Polymers
I.6.1. Introduction
To assist with the problems in large bone defects, the development of a three-dimension (3D)
scaffold, with electroconductive properties is of interest as it can act as a substrate for capacitive
coupling electrical stimulation, while remaining non-invasive. A variety of materials can be used
to fabricate 3D electroconductive implants, but in order to fabricate an implant for bone
regeneration, the material must be able to be electrically stable in in aqueous environment, remain
biocompatible, and present high mechanical flexibility, light weight as well as low thermal
conductivity. Due to these requirements, interest has been given to the use of conductive polymers
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(CPs) to act as an electroactive material that can conduct electricity while supporting cellular
adhesion and growth.

I.6.2. Electrically conductive polymers
CPs are electroactive materials consisting of a conjugated backbone. CPs allow excellent
control of the electrical stimulus, possess particularly good electrical and optical properties, have
a high conductivity to weight ratio, and can be made biocompatible, biodegradable, and porous.47
Furthermore, a great advantage of conductive polymers is that their chemical, electrical, and
physical properties can be tailored to the specific needs of their application by incorporating
antibodies, enzymes, and other biological moieties.48,49

CPs were first discovered by Dr. Shirakawa in 1977, with the synthesis of the polyacetylene
polymer. Normally, polyacetylene acts as a semiconducting polymer with low conductivity, yet
when oxidized in the presence of iodine vapor, the conductivity increases by 10 million-fold.47
This phenomenon was titled “doping” and is essential for the conductivity of all CPs studied today
(Table 1.2). Till now, four main types of CPs including polyacetylene, polyaniline, polypyrrole,
and polythiophene have been widely studied. Among them, polyanilines and polypyrroles via
doping show conductivities around 100 S cm−1, while polyacetylenes and polythiophenes could
achieve electrical conductivities up to approximately 103 S cm−1.50 The CPs studied today have
been used in various industrial and biomedical applications. For instance, CPs have been used in
the areas of super capacitors, light emitting diodes, solar cells, antistatic coatings, batteries, and
displays in mobile phones.51 In the biomedical field, CPs have been used as biosensors, neural
electrodes, bioactuators, drug delivery systems, and tissue scaffolds.34,49
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Table 1.2. List of conductive polymers that are studied today.

Polypyrrole (PPy)
Polyaniline (PANI)
Poly(3,4ethylenedioxythiophene)
(PEDT, PEDOT)

Poly(2,5thienylenevinylene)
(PTV)
Poly(3-alkylthiophene)
(PAT)
Poly(p-phenylene) (PPP)

Poly(p-phenyleneterephthalamide) (PPTA)

Polyfuran (PFu)

Polyacetylene (PAc)

Polyisoprene (PIP)

Poly(isothianaphthene)
(PITN)

Polybutadiene (PBD)

Polythiophene (PTh)

Poly-p-phenylenesulphide (PPS)

Poly(α-naphthylamine)
(PNA)

Polythiophene-vinylene
(PTh-V)

Poly(pphenylenevinylene)
(PPV)

Polyazulene (PAZ)

Poly(3octylthiophnene-3methylthiophene)
(POTMT)
Poly(p-phenyleneterephthalamide)
(PPTA)

I.6.3. Charge transfer and doping mechanism
These special polymers are able to achieve their conductive traits thanks to the ease with
which electrons jump within and between the chains of the polymer. As mentioned, CPs possess
a conjugated backbone (Figure 1.8), meaning that it is formed by a series of alternating single and
double bonds.47 Single and double bonds both contain a chemically strong, localized σ-bonds,
while double bonds also contain less strongly localized π-bonds. The p-orbitals in the series of πbonds overlap each other, strengthening the connection between their atoms by attracting electrons
above and below the plane of the molecule. These p-orbitals form delocalized orbitals allowing
the electrons to move more freely between the atoms.
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Figure 1.8. Schematic of a conjugated backbone, highlighting the σ- and π-bonds present in the
structure of CPs. The π-bonds are present in double bonds, and the p-orbitals presented with these
bonds allow the delocalization of electrons.47

The mobility of electrons and the polymer conductivity can be further enhanced with the
incorporation of a dopant. Doping is the process of introducing impurities (dopants) as a means of
increasing the conductivity of the CP (Figure 1.9). During this process, the number of electrons in
the polymer changes, by either removing or adding electrons to the atoms. Removing electrons
(known as p-type doping) creates empty spaces in the outermost orbital of the atom, allowing for
the remaining electrons to move around more freely. Adding electrons (known as n-type doping)
forces an atom to create another orbital, giving the electrons more space to move around and hop
from atom to atom, so long as the orbital does not become full.
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Figure 1.9. Doping process of polythiophene polymer. A) chemical structure of undoped
polythiophene polymer. B) p-type doping, creating positive polarons and bipolarons. C) n-type
doping, creating negative polarons and bipolarons.52

The electrons that are removed or added to the polymer system, from the introduction of a
dopant, get relocalized in the polymer chain as polarons or bipolarons. A polaron is a loosely held
electron that is surrounded by crystal lattice distortion and a bipolaron is two polarons in the same
system.53 As an electrical potential is applied to a CP, the dopant starts to move in or out of the
polymer, disrupting the stable backbone and allowing charge to be passed through a polymer in
the form of polarons or bipolarons (Figure 1.10).47,54 The doping process also inserts a counter-ion
into the polymer backbone, stabilizing the polymer and neutralizing the charge. In CPs, p-type
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doping is generally more common than n-type because most n-type doped conducting polymers
are not as stable in the air due to oxidation by oxygen (O2).54

A.

B.

C.

Figure 1.10. Schematic of a dopant entering a polymer system. A) Dopant (D) enters the system
and adds or removes an electron (e-). B) crystal lattice distortion of the polymer chain occurs
around the electron, creating a polaron. C) the polaron (P) acts as a charge carrier and can travel
along the polymer chain, conducting electricity.47

Another form of doping is termed secondary doping, which is responsible for increasing the
conductivity of CPs even further by introducing another dopant to a polymer system that has
already been previously doped. Secondary dopants can be defined as an inert substance which,
when applied in the form of a liquid and/or vapor to a CP already doped, induces significant
changes in molecular conformation.55 Different dopants such as ionic liquids, surfactants, metal
oxides, solvents and solid electrolytes can be employed as secondary dopants. Various studies have
already been performed on CPs with solvents such as sulfuric acid and dimethyl sulfoxide as a
secondary dopant to increase the resultant conductivity.56
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I.6.4. Poly(3,4-ethylenedioxythiophene)
A. Introduction
Poly(3,4-ethylenedioxythiophene) (PEDOT) has gained a lot of interest as of recently.
PEDOT is a derivative of the conductive polymer family known as polythiophenes. PEDOT can
be synthesized through polymerization of the bicyclic monomer 3,4-ethylenedioxythiophene
(EDOT) (Figure 1.11-A). PEDOT has proven to have a higher and more stable conductivity when
compared to other commonly used conductive polymers. This is due to PEDOT’s structure, which
has a dioxyalkylene bridging group across the 3- and 4-positions of its heterocyclic ring (Figure
1.11-b). The main property of PEDOT that ensures its unique place among conducting polymers
is its high and stable electrical conductivity.57 Today, PEDOT is used in capacitors, touch panels,
organic solar cells, biosensing and bioengineering applications as neural electrodes, nerve grafts
and heart muscle patches.47,52

A A.
.

B.

Figure 1.11. Chemical stucture of A) 3,4-ethylenedioxythiophene (EDOT), B) Poly(3,4ethylenedioxythiophene) (PEDOT).58

B. Applications of PEDOT
PEDOT was discovered by researchers at Bayer AG in the late 1980s and has since become
one of the most important conductive polymers to use. The main reason is due to the conductivity
of PEDOT which has shown to be only one order of magnitude lower than conductive metals,
namely silver and copper.58 Not only does PEDOT exhibit high conductivity values, but its
conductivity has proven to remain stable over time. Alongside this, PEDOT has shown to have
good thermal, chemical, and enviornmental stability when compared to other conductive polymers,
while also remaining biocompatible and non-toxic to various cell types.49,58,59 Although PEDOTs
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use in industry is prevelent, its use in medicine, biotechnology, and tissue engineering is becoming
more of an interest. Numerous studies have been performed on PEDOT with various cell types.
For instance, synthesized PEDOT films were investigated for their biocompatibility by seeding
fibroblasts. Subcutaneous implantation of the PEDOT films was also studied. Their results showed
that PEDOT films exhibit very low intrinsic cytotoxicity and no inflammatory response upon
implantation.60 PEDOT has also been used in the development of a highly porous, conductive
scaffold based on a PEDOT: polystyrene sulfonates (PSS) material that supported the
differentiation of pre-osteogenic precursor cells (MC3T3-E1) into mature osteoblasts.61 PEDOT
coated substrates have also been tested to sustain electrical stimulation. PEDOT has been able to
demonstrate the support of cellular adhesion, migration, and proliferation.62 With growing
significance in the application of PEDOT, the routes of synthesis have become an interest to
researchers.

C. Synthesis of PEDOT
PEDOT can be synthesized through three main polymerization reactions from the bicyclic
monomer 3,4-ethylenedioxythiophene (EDOT) (Figure 1.11-A):

-

Oxidative chemical polymerization of EDOT-based monomers,

-

Electrochemical polymerization of EDOT-based monomers, and

-

Transition metal-mediated coupling of dihalo derivatives of EDOT.

The oxidative chemical polymerization is a simple method that yields a black, insoluble, and
infusible compound of PEDOT. The oxidative polymerization mechanism for PEDOT can be
described as a three-step mechanism (Figure 1.12). First, EDOT monomer is oxidized by the
oxidant to form its cationic radicals (Figure 1.12-A). Iron (III) complexes have proved to be
efficient oxidants, for the synthesis of PEDOT including ferric chloride (FeCl3) and Iron (III) paratoluene sulfonate or tosylate (Fe(Tos)3).58 During the second step, dimerization of the free radicals
occurs, and the resultant doubly oxidized protonated dimer subsequently undergoes deprotonation,
resulting in an energetically favorable neutral dimer. The dimers can be reactants in a subsequent
oxidation process for further chain growth. This step-polymerization thus proceeds to form neutral,
undoped PEDOT polymers or oligomers (Figure 1.12-B). In the final step, the neutral PEDOT is
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doped by the oxidant. Meanwhile, the anion from the oxidant complex is incorporated as the
counterion to stabilize the charged PEDOT (Figure 1.12-C).50

A.

B.

C.

Figure 1.12. Mechanism for chemical oxidative polymerization of PEDOT using EDOT monomer
and Fe(III) complex. A) Fe(III) oxidizes EDOT and is reduced to Fe(II). B) Two oxidized EDOT
combine into a 2-EDOT dimer which is further deprotonated by surrounding water molecules. C)
Steps (A) and (B) are repeated in order to form polymer chains and remaining Fe(III) ions dope
the PEDOT while Tos- ions are inserted as counteranions in order to stabilize the doped PEDOT.58

In the electrochemical polymerization of PEDOT, instead of using oxidants, the EDOT is
oxidized by an applied potential to form highly transmissive sky-blue doped PEDOT films at the
electrode. The electrodeposition is typically carried out in a three-electrode system containing the
electrolyte solution and EDOT monomers.63 During the polymerization, the anion of the
electrolyte becomes the counterion of the doped PEDOT that largely influences the morphology
and mechanical stability of PEDOT films. Therefore, more options for counterions can be
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introduced in the form of salts. By adjusting the counterions, the resulting conductivities of the
electrically polymerized PEDOT films can be affected.64 Furthermore, this electrochemical
methodology enables the control of the reaction via changing the applied potential value.50

The final method of PEDOT synthesis, uses transition metal catalyzed coupling of activated
organometallic derivatives and the EDOT monomer to directly form neutral PEDOT.65 This
method is not as common when compared to the other routes of PEDOT synthesis. The
electrochemical polymerization is the widely used method to synthesize PEDOT. This method
yields small amounts of PEDOT, since it is conducted on small electrodes. On the other hand, the
oxidative chemical polymerization is flexible, low cost and large amounts of PEDOT can be
prepared. The resulted PEDOT can be combined with other polymers to enhance mechanical and
biological properties of PEDOT.

I.7. Biofunctionalization of Biomaterials
I.7.1. Introduction
The design and synthesis of novel and effective biomaterials, such as PEDOT, for bone tissue
engineering applications is needed. It is important that biomaterials appropriately function in their
intended way while in a biological system. To establish this, biofunctionalization of the biomaterial
is important. Biofunctionalization is essentially the modification of a material to have biological
function and stimulus, whether permanent or temporary while at the same time being biologically
compatible.66 This allows the biomaterial to retain the key physical properties of a biomaterial
while modifying only the outermost surface to influence the biointeraction. Commonly observed
interactions of any material with a biological system cover adsorption or adhesion processes of
proteins and bacteria or platelets as well as phagocytosis and fibrous encapsulation.67 Effective
surface modification of biomaterials could lead to the development of bioactive biomaterial
substrates capable of controlling cellular interactions (through integrins) and improving cell
growth, differentiation and ECM synthesis.66 There are numerous ways to achieve bioactivity, but
a common way to do so is by loading a biomaterial substrate with biomolecules relating to the
extracellular microenvironment of specific tissue, such as ECM proteins and growth factors. Once
loaded, the biomolecules can be released in a prolonged way by diffusion or polymeric network
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breakdown, allowing for interaction with surrounding cells and enabling the restoration of tissue
formation.68 Some of the most common ECM proteins studied to enhance cellular adhesion,
migration and proliferation include collagen, laminin, and fibronectin.69-71 Growth factors such as
transforming growth factor beta (TGF-β), insulin-like growth factor-1(IGF-1), BMP-2, and
vascular endothelial growth factor (VEGF) can also be utilized to enhance signaling pathways that
can promote cellular proliferation and differentiation as well as protein synthesis, stimulating
tissue formation.72-75

I.7.2. Biofunctionalization of PEDOT
In conductive polymers, the bioactivity has shown to be enhance through
biofunctionalization using different molecules. For example, fibronectin was incorporated to
polypyrrole nanoparticles to enhance cell adhesion and proliferation on a polypyrrole/PLLA
composite membrane.76 Studies have also examined the biofunctionalization of PEDOT with
laminin peptides to enhance cell adhesion and differentiation on the rat pheochromocytoma (PC12)
cell line.77-78 Studies are even looking at the synthesis of PEDOT with biomolecules as dopants,
termed PEDOT:biopolymers, to enhance the biocompatibility and reduce the cytotoxicity
commonly seen in commercialized poly(3,4-ethylenedioxythiophene) polystyrene sulfonate
(PEDOT:PSS).79

PEDOT:biopolymer

aqueous

dispersions

synthesized

by

chemical

polymerization have been reported using DNA, sulfated cellulose, dextran sulfonate, hyaluronic
acid, heparin, chondroitin sulfate, pectin, and guar gum.79-85 In the cases of PEDOT:DNA and
PEDOT:sulfate cellulose, higher conductivities were reported in comparison to PEDOT:PSS.80,81
Another important factor to consider when modifying a biomaterial with biofunctionalization is
infections. Prosthetic joint infections (PJIs) are one of the most feared complications that often
result in revision of the artificial joint with serious consequences for the patients and high costs for
the respective health systems. Bone destruction by bacterial infection, also known as osteomyelitis,
is a major problem which require surgical removal of the infected tissue and the use of antibiotics
to reduce bacterial growth.86 In the case of biofilm growth, the removal of the bone implant may
delay the healing process as well.87 Therefore, modifying PEDOT to enhance its efficacy while
addressing serious issues such as infections is important and could be very helpful.
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A. Dimethyl sulfoxide
Dimethyl sulfoxide (DMSO) is an organic polar aprotic molecule widely used as solvent in
toxicology and pharmacology, for cryopreservation of cells, and as penetration enhancer during
topological treatments (Figure 1.13). At high doses, it is generally accepted that DMSO is toxic.
However, DMSO is not nontoxic below 10% (v/v) and the FDA has classified DMSO in the same
class as ethanol, namely class 3 solvent, which is the safest category with low toxic potential at
levels normally accepted in pharmaceuticals.88 Today DMSO is used at relatively low
concentrations and can be used to induce anti-inflammation, nerve blockage (analgesia), diuretics,
vasodilation and muscle relaxation.89 In cell biology, DMSO is also used as inducer of cell
differentiation, free radical scavenger and radioprotectant, but most often for cryopreservation.90
Furthermore, DMSO has been investigated in tandem with conductive polymers to act as a
secondary dopant as well as an inducer for osteoblast differentiation.91-93

Figure 1.13. Chemical structure of DMSO.132

Depending on the cellular context, DMSO is capable of inducing or inhibiting cell
proliferation, apoptosis and differentiation. DMSO induces the differentiation of many cell types
including mammary adenocarcinoma LA7 cells and osteoblasts.91,94 Interestingly, DMSO
enhanced the expression of primary human osteoblast differentiation markers and extracellular
matrix mineralization making it an attractive molecule to use in bone growth studies. 95 As
previously mentioned DMSO can also affect conductive polymers. DMSO has been used as a
secondary dopant to further increase the electrical conductivity of PEDOT.56 DMSO has even been
recorded to enhance the conductivity of PEDOT by three orders of magnitude.96 DMSO has also
been proven to have an effect on harmful bacteria. Studies have shown DMSO as an antimicrobial
activity against Escherichia coli, Pseudomonas aeruginosa, and Bacillus megaterium.97
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B. Graphene oxide
A polymeric PEDOT biomaterial can be further modified with the addition of graphene
oxide (GO). Polymeric biomaterials exhibit excellent biocompatibility and biodegradability but
lack the ability to withstand high forces acting upon them. In order to improve their mechanical
strength, recent interest has been given to the incorporation of graphene derivatives within the
natural and synthetic biomaterials such as alginate, chitosan, and bioactive glass.98-100 Besides
enhancing the physical properties, graphene derivatives also promote cell proliferation and
differentiation, owing to their excellent biocompatibility under limited concentrations.34 One
graphene derivative of interest is graphene oxide.

Graphene oxide (GO) is a single-layer sheet of aromatic carbon atoms with superior strength,
and suitable electrical conductivity which makes it appropriate for various fundamental and
medical applications.101 GO is negatively charged and possesses many oxygen containing
functional groups, such as carboxyl, hydroxyl and epoxide, rendering it hydrophilic and dispersible
in aqueous solutions, which make it an excellent dopant for conducting polymers (Figure 1.14).102
Because of its excellent biocompatibility under recommended concentrations, graphene and its
derivatives have shown promising results in regulating cell behavior, loading, and releasing of
drugs and genes.103 GO differs from graphene in that it forms a uniform and stable suspension in
water, whereas graphene tends to from aggregates. Interestingly, GO has recently been shown to
act as a promoter of endothelial, hepatocyte, neuronal, and MSCs proliferation and maturation.104
This is accomplished by hydrophobic and electrostatic interactions with the proteins of the
microenvironment.34 These unique characteristic of GO makes it the material of choice in bone
tissue engineering.
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Figure 1.14. Graphene-family nanomaterials.105

GO has also drawn considerable attention in nanomedicine for its antimicrobial potential to
resistant bacteria such as gram-positive Staphylococcus aureus and gram-negative Escherichia
coli.106 GO has the ability to physically damage microorganisms by penetrating and cutting the
cell membrane, wrapping cells inducing mechanical stress and extracting phospholipids from lipid
membranes.107 GO can also insert into bacterial membranes, creating a breakthrough which Van
Der Walls forces and the hydrophobic properties of graphene extract phospholipids from the lipid
layers of the bacterial membranes.108 This causes irreversible damages, making the effects of GO
on bacteria very effective. The incorporation of GO in PEDOT, will enhance the mechanical
properties and the conductivity of the polymer. Once an electrical potential is applied, the GO will
be released from the polymer, inhibiting the growth of surrounding bacteria.

I.8. Biodegradable Polymers
I.8.1. Introduction
Despite the growing interest of PEDOT in industrial and biomedical applications, the
polymer is too brittle to be formed into a scaffold by itself. PEDOT also does not degrade overtime
and to this end, it must be mixed with another safe and biodegradable polymer. Biodegradable
polymers are used to fabricate biomaterials and are desirable, since they break down, excrete, or
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are absorbed and do not need removal or surgical interventions after implantation. These polymers
should degrade at a rate comparable with the healing and regeneration process and help ensure
tunable mechanical properties. Moreover, the polymer should be biocompatible and should not
elicit immune reactions. The degradation products should be nontoxic, metabolized, and cleared
easily as well.109

I.8.2. Poly (є-caprolactone)
There are a variety of natural and synthetic biodegradable polymers used today, but one
that is of current interest is the synthetic polymer Poly (є-caprolactone) (PCL). PCL is a
semicrystaline polymer and a member of the polylactone family.109 PCL is a thermoplastic
polymer with several desirable features, including good stability under ambient conditions and
ease of processability (thermal and solution).110 PCL is mainly synthesized by ring opening
polymerization of ε-caprolactone (Figure 1.15). The use of PCL is favorable from the biomedical
perspective as it is approved by the U.S. Food and Drug Administration (FDA) for certain clinical
purposes and offers a slow degradation rate up to several years.111 This polymer has been
successfully incorporated as an implantable biomaterial for medical applications, including sutures
and wound dressing, cardiovascular tissue engineering, nerve regeneration, and bone tissue
engineering.110 Its use as a vehicle for controlled delivery of therapeutic molecules (e.g., drug,
protein, gene), has also been extensively explored.112

Figure 1.15. Synthesis of polycaprolactone (PCL) by ring opening polymerization.110
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I.9. Scaffold fabrication
I.9.1. Introduction
As previously stated, tissue engineering involves the integration of scaffolding materials,
cells, and/or biological factors to promote tissue growth. To accomplish this, it requires a scaffold
to provide a transitional three-dimensional (3D) support for cell migration, attachment, and
proliferation, as well as to provide a vector for delivery of biochemical factors. The scaffold should
also offer mechanical as well as biological influences to guide the maturation and integration of
cells to form tissues. In parallel with these features, it is important that scaffolds aim to mimic the
componential and structural aspects of the extracellular matrix (ECM) to facilitate cell recruiting,
adhesion, proliferation, differentiation, and neo tissue genesis. From a structural perspective,
natural ECM consists of various interwoven protein fibers with diameters ranging from tens to
hundreds of nanometers. The nanoscale structure of ECM offers a natural network of nanofibers
to support cells and to present an instructive background to guide cell behavior. Developing
scaffolds that mimic the architecture of tissues at the nanoscale is one of the major challenges in
the field of tissue engineering.113

I.9.2. Electrospinning
Various processing techniques such as phase separation, self-assembly, and electrospinning
have been developed to fabricate nanofibrous scaffolds, however, the electrospinning process has
attracted the most attention. The electrospinning process not only has the ability to generate fibers
similar to the fibrous structure of native ECM but can do so with a wide range of materials while
remaining cost effective and straightforward. The large surface area of electrospun nanofibers as
well as their porous structure favors cell adhesion, proliferation, migration, and differentiation
making electrospinning a well-suited process for the fabrication of scaffolds for tissue engineering.

The electrospinning process uses a high voltage (5 to 30 kV) to create an electric field
between a droplet of polymer solution and a metallic collector plate (Figure 1.16). During this
process, the polymer solution is pumped through a syringe at a constant rate, forming a droplet at
the end of a needle. The electrostatic field and the electrostatic repulsion of charges act on the
polymer droplet and are opposed by the surface tension of the droplet and the viscoelastic forces
of polymer. When electrostatic repulsion charges exceed the surface tension, stretching of the
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polymer droplet occurs, and the droplet takes the form of a cone, named a Taylor Cone. This cone
is then stretched into a continuous fibrous jet and moves toward the collector. The solvent
evaporates on the way down and the jet solidifies to form a nonwoven fibrous membrane.113-115
The standard electrospinning system consists of four parts: a spinneret with a metallic needle, a
syringe pump, a high-voltage power supply, and a grounded collector (Figure 1.16). These
collectors can range in shape and size from being a flat sheet or cylindrical mandrel (Figure 1.17).

Figure 1.16. Electrospinning schematic setup.116

A combination of different parameters can influence the electrospinning of nanofibers. These
parameters fall into three distinct categories:

A. Solution parameters
When focusing on the solution, there are two general requirements for successful
electrospinning. These requirements are a sufficient molecular weight for the polymer and the
availability of a suitable solvent to dissolve the polymer creating a homogenous solution. In
general, lowering the molecular weight of the polymer tends to generate beads rather than fibers
because of the limited chain entanglements.115 The solvent nature is also a vital factor for the
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electrospinning process. Factors such as the volatility and dielectric constant must be examined to
determine the best solvent for a given polymer. The volatility must be just right so the fibers are
able to solidify when they come in contact with the collector. The dielectric constant of the solvent
controls the magnitude of electrostatic repulsion among the surface charges residing on the jet. In
general, with increasing of the dielectric constant, the applied voltage required to achieve a stable
jet will be increased.117

B. Apparatus parameters
The apparatus parameters include the applied voltage, the distance between the needle and
collector, the flow rate, the needle diameter, and the collector material, shape, size, and/or rotation
speed, if applicable. These parameters work together to control the morphology and diameter of
the fibers; therefore, it is necessary to optimize the parameters together to obtain the desired results.
The applied voltage, usually produced from a static direct current (DC) power supply, generates
the electrical field between the solution and the collector plate, determining the amount of charges
carried by the jet and the magnitude of electrostatic repulsion among the charges, as well as the
strength of the interactions between the het and the external electrical field. It should be noted that
higher voltages typically favor the formation of thinner fibers.117 The collector is a conductive
material such as aluminum foil and is electrically grounded so that there is a stable potential
difference between the source and the collector. These collectors can also vary in shape and size,
depending on what is desired (Figure 1.17). Rotating or stationary collectors are also determined
based on the experiments whereas rotating collection has been used to collect aligned fibers and
assist in the evaporation of solvents with low volatilities.
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Figure 1.17. Different collector designs with their corresponding collected fiber organization.118

C. Environmental parameters
The environmental parameters mainly include the relative humidity and temperature during
the electrospinning process. Both the relative humidity and temperature influence the evaporation
rate of the solvent and thus the solidification rate of the jet, whilst an elevated temperature may
also have an influence on the surface tension and the viscosity of the polymer solution, thus
impacting the diameter of the fibers.117

Although the electrospinning process is a beneficial technology when attempting to create
structures that mimic that nanofibrous makeup of the native ECM, the traditional electrospinning
process only allows for the production of two-dimensional designs. Given that bone represents a
3D design, electrospinning is not the only technology that is to be used for the fabrication of a
scaffold. The additional use of 3D printing technologies is thus required to the fabrication of a 3D
scaffold suitable for bone tissue engineering.

I.9.3. 3D printing
3D printing, or additive manufacturing, enables the fabrication of complex forms with high
precision by adding materials layer by layer to form the final shape and is a valuable tool in the
fabrication of scaffolds with desired properties and well-controlled spatial chemistry and
architecture.119 3D printing mainly involves the use of Computer Aided Design (CAD) software
to establish a model; the model is imported into slicing software, and a 3D printer is used to print
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the model. Tissue engineering can use this software to produce patient-specific scaffolds which is
beneficial in the world of personalized medicine. The main 3D printing categories that use
polymers for product formation are fused deposition modeling (FDM), selective laser sintering
(SLS), stereolithography (SLA), and inkjet printing.119

A. Fused deposition modeling
FDM was developed and patented by Scott Crump in the late 1980’s and remains one of the
most commonly used rapid prototyping techniques to this day.119 FDM is based on the heating of
a thermoplastic polymer into a molten state, which can be extruded through a nozzle onto a
platform, deposited in a layer-by-layer fashion, creating a 3D construct.120 The resolution of this
product is controlled by the nozzle diameter, print speed, the angle, and the distance between fibers
of the subsequent layers (Figure 1.18-A).
A.

B.

Figure 1.18. Schemes of (A) FDM and (B) SLS additive manufacturing techniques.119

B. Selective laser sintering
SLS was developed and patented by Deckard and Joe Beaman in 1989.121 In this technique,
a laser beam is used to melt a thin layer of powder material. The beam heats the material and fuses
them together to draw a 2D shape according to the computer program. After one layer is produced,
the built platform moves down one layer of thickness, and a new layer of powder is spread on the
surface of the platform by a piston to sinter on the next layer. This is repeated until the final
structure is built (Figure 1.18-B).122
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C. Stereolithography
SLA was first discovered in the early 1980s by Hideo Kodama and was later improved upon
by other engineers.123 SLA is based on the selective polymerization of a liquid, photosensitive
resin by a light source, such as UV light, LED light or a laser. SLA is a dynamic version of
photolithography as it uses a narrow beam of light to cure the polymer to produce a desired pattern.
The light selectively polymerizes the resin according to the CAD model. After the first layer is
produced, the platform lowers and a fresh resin material is added to polymerize and create the
second layer, and so forth. Finally, the uncrosslinked resin is washed, and the construct is postcured with UV in order to increase the stability of the product (Figure 1.19-A).119

A.

B.

In

Figure 1.19. Schemes of (A) SLA and (B) Inkjet printing techniques.119

D. Inkjet printing
Inkjet printing was the first developed by the Hewlett-Packard Company in the 1970s as a
2D printing method. 3D inkjet printing uses a similar cartridge, placed in the printer head to deposit
small droplets of ink via thermal or piezoelectric energy. In thermal inkjet printing ejection occurs
by the help of small air bubbles created by an increase in temperature in the printing head. In
piezoelectric inkjet printing, applying different potentials to the piezoelectric crystal in the printer
generates the pressure needed to eject the ink droplets from the nozzle. As the print head raster
scans over a surface, multiple layers are built up in a layer-by-layer process, predefined by the
CAD software. Each deposited layer is then cured in between successive depositions (Figure 1.19B).124,125 Table 3 summarizes the advantages and disadvantages of each technique discussed.
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Table 1.3. Comparison of different additive manufacturing technologies
Technique
Fuse Deposition
Modeling (FDM)

Selective Laser
Sintering (SLS)

Stereolithography
(SLA)

Inkjet Printing

Material
Thermoplastic
polymers

Powder
materials
(ceramics,
metals, and
thermoplastic
polymers)
Photopolymers

Polymer
solutions,
Liquids

Advantage
• Multiple extrusions with different
materials
• Simple process
• Cost effective
• Fast process
• Solvent free process

• Ability to fabricate large and
complex scaffolds
• Does not require support
structures during production
• Solvent free process
• Each layer is printed at the same
time
• Decreased printing time
• External geometry and internal
architecture can be precisely
controlled
• Easy to fabricate complex
scaffolds
• Fast fabrication
• Inexpensive
• High resolution
• Has the ability to incorporate
biomolecules and living cells while
printing

Disadvantage
• Limited number of usable
materials (biocompatible
materials)
• Difficult to find materials with
proper melt viscosity
• High temperatures
• Difficult to replicate geometries,
low resolution
• Product surface is not smooth
and needs polishing
• Requires long wavelength or
high energy source
• Slow process
• Expensive
• Few biocompatible materials are
available for use
• Support structure required

• Limited choice of biomaterials
to use
• Lower mechanical strength

I.9.4. 3D electrowriting
Recent advancements in additive manufacturing technologies have built off current 3D
printing technologies with the incorporation of electrospinning. Traditional electrospinning
techniques are very advantageous in the fabrication of nanostructures, while most 3D printing
technologies can only obtain microstructures. However, traditional electrospinning lacks precise
fiber alignment, which 3D printing is capable of achieving. Therefore, the combination of
electrospinning with 3D printing technologies are being researched more than ever in the area of
tissue engineering to create highly precise nanocomposites. This phenomenon is known as
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electrowriting. Electrowriting applies the same principle as traditional electrospinning but with a
lower voltage and a reduce working distance between the needle tip and the collector plate (Figure
1.20).119 The change in electrospinning parameters allows for the controlled deposition of fibers
and precision in the spun structures. With the reduced working distance, bending instability that
arises in traditional electrospinning is significantly restrained, so that fibers can be deposited as
straight lines rather than randomized patterns. The collector is placed on a platform that moves
along the x and y-axis, and this movement is controlled by the computer program that enables
laying fibers down in a predetermined path to obtain a desired pattern or shape, in a layer by layer
fashion.

Figure 1.20. Schematic of electrowriting.119

Similar to traditional electrospinning, two electrodes are connected to the high voltage power
supply. The positive end electrode is connected to the printhead and the negative end electrode is
connected to the print bed, enabling an electrical field between the two components. This stretches
the polymer solution toward the collector and the reduced working distance helps control the
alignment of the fiber. Using CAD software, the fibers can be extruded in a predefined path,
creating a 3D structure.

There are two forms of electrowriting being studied today. These include solution
electrowriting and melt-electrowriting (MEW). As previously mentioned, solution electrowriting
mimics the set up and process of traditional electrospinning, but with a reduced working distance.
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This method requires a polymeric solution to be extruded from the nozzle much like in traditional
electrospinning, and as such, the parameters needed to control this process mimic those of
electrospinning.128 MEW on the other hand uses polymer melts, which are heated to a specific
temperature (melting temperature) to create a flowable polymer.129 The same electrical field exerts
a force on the polymer like in electrospinning, but instead of evaporation of a solvent during fiber
collection, the polymer simply cools on the grounded collector, creating a fiber. Although similar,
MEW requires additional parameters to consider such as processing temperature, applied pressure
during extrusion, and collection speed.130 Outside of these requirements, the voltage, nozzle to
collector distance, nozzle size, and environmental parameters must also be controlled, similar to
traditional electrospinning. Both methods are seen as novel and effective methods for produce 3D
nanofibrous structures.

I.10. Proposed Study
I.10.1. Introduction
The treatment of large and nonunion bone defects remains a significant challenge for both
patients and orthopaedic surgeons worldwide. Current treatments strategies are complex and costly
and may be associated with undesirable side effects such as morbidities, chronic pain, and
amputations.9 Tissue engineering has made great strides in developing artificial constructs for bone
repair using biomaterials. However, there remain substantial challenges in creating bioactive
scaffolds that mimic the piezoelectric properties of bone and the architecture of the ECM, so they
can significantly modulate stem cell performance.

Electroactive biomaterials in tandem with electrical stimulation therapy may offer a
solution for regenerating bone in difficult to heal defects. Conductive polymers, such as PEDOT
is of great interest in tissue engineering due to excellent electrical stability and biocompatibility.62
To enhance its conductivity and antibacterial properties, dopants such as DMSO can be added.56,97
GO can also be introduced as an oxidant to enhance conductivity as well as the mechanical
properties.131 PCL is a FDA-approved biodegradable polymers that have been used in various
tissue engineering applications. Together, these components may have the ability to form a
bioactive and highly electroconductive biomaterial for bone regeneration.
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The advanced 3D printing technology of melt-electrowriting (MEW) combines principles of
electrospinning and additive manufacturing to allow for the fabrication of 3D scaffolds that aim
the componential and structural aspects of the extracellular matrix. By incorporating a GO/DMSOdoped PEDOT biomaterial with a PCL polymer, an electrically conductive polymer melt may be
utilized for MEW to fabricate a novel nanofibrous electroconductive scaffold for bone tissue
engineering applications.

I.10.2. Objectives
The overall goal is to develop a biodegradable and conductive scaffold to mimic the
piezoelectric properties of bone and the architecture of the ECM. The strategies include the
synthesis of electroconductive GO/DMSO-doped PEDOT with bioactive properties. The
fabrication of a biodegradable 3D scaffold by combining the newly synthesized PEDOT with
biodegradable PCL polymer. This overarching study can be separated into 2 objectives:

Objective 1. The synthesis and characterization of GO/DMSO-doped PEDOT nanoparticles:
Determine the optimal polymerization conditions for three types of PEDOT
nanoparticles, (pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped PEDOT).
Objective 2. The fabrication of a PCL- [GO/DMSO-doped PEDOT] 3D scaffold: Fabrication of a
PCL-[GO/DMSO-doped PEDOT] composite and determine the printing parameters
using MEW technology.

I.10.3. Hypothesis
1) The use of different solvents in the polymerization of PEDOT composites will affect
the ultramorphology and reaction yield.
2) The incorporation of DMSO and GO will enhance the doping level of PEDOT.
3) PEDOT will show no cytotoxic effects on BMSCs.
4) MEW technology will successfully fabricate a nanofibrous composite scaffolds.

I.10.4. Approach
1. Synthesize GO/DMSO-doped PEDOT nanoparticles by oxidative polymerization using
different solvents.
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2. Study the physicochemical properties of GO/DMSO-doped PEDOT nanoparticles.
3. Culture BMSCs on GO/DMSO-doped PEDOT nanoparticles and test cell adhesion,
cytotoxicity and proliferation.
4. Synthesis PCL- [GO/DMSO-doped PEDOT] biodegradable and conductive composite
using solvent casting technique.
5. Design and fabricate a PCL- [GO/DMSO-doped PEDOT] conductive 3D scaffold, and
study printability.

I.10.5. Significance
This study shows clinical significance in the field of bone tissue engineering and
regenerative orthopaedics as the PCL-[GO/DMSO-doped PEDOT] based conductive scaffolds
could serve as an effective stand-alone electroconductive bone graft substitute or in combination
with electrical stimulation therapy. The novel scaffold also shows promise in harnessing the ability
to enhance bone regeneration while at the same time inhibiting bacterial growth. This scaffold may
serve as a platform to study electrical stimulation on multiple cell types, including bone, cartilage,
tendons, nerve, muscle, skin and immune cells and ultimately lead to the development of a
bioelectronic device to apply electrical stimulation in vivo.
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CHAPTER II

MATERIALS and METHODS
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II.1. Polymerization of EDOT
II.1.1. Synthesis of pure PEDOT
Three separate types of PEDOT nanocomposites were synthesized by oxidative
polymerization of 3, 4-Etylenedioxythiophene monomer (EDOT) (Tokyo Chemical Industry,
Tokyo, Japan) in the presence of GO, DMSO (Fisher Bioreagents, Pittsburgh, PA) and ferric
chloride hexahydrate (FeCl3•6H2O) (Acros Organics, Fair Lawn, NJ) (Figure 2.1). For pure
PEDOT, 0.8 g of FeCl3•6H2O anhydrous powder was dissolved in 10 ml of various solvents and
added to EDOT at a 1:3 ratio of monomer to oxidant (EDOT: FeCl3•6H2O). Previous studies have
indicated that the 1:3 ratio yields PEDOT polymers with the highest polymerization degree,
conjugation length, and crystallinity.133 The different solvents used for polymerization included
deionized water (H2O), ethanol (EtOH), methanol (MeOH), and 50/50 mixtures of H2O/ethanol
(H2O/EtOH), H2O/methanol (H2O/MeOH), and ethanol/methanol (EtOH/MeOH) (all from Fisher
Chemical, Hampton, NH). These solutions were briefly mixed until FeCl3•6H2O was dispersed,
leaving a red-orange solution. 200 µl of aqueous EDOT monomer was then added to the FeCl3
solution and sonicated for 30 mins. The solution was transferred to a shaking incubator and
shacked for 18 h at 70 °C and 50 RPM. A similar protocol was followed for the synthesis of
DMSO-doped PEDOT and GO/DMSO-doped PEDOT with some additional steps to introduce
DMSO and GO when appropriate.

FeCl3
Solvent
DMSO
GO

Incubate
18h 70 °C
50 RPM

EDOT
Sonicate

Sonicate

H2O/MeOH
(1:1 vol ratio)

Wash

Dry
PEDOT

Figure 2.1. Synthesis of the different PEDOTs by oxidative polymerization using FeCl3.
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II.1.2. Synthesis of DMSO-doped PEDOT
For the synthesis of DMSO-doped PEDOT, 0.8 g of FeCl3•6H2O anhydrous powder was
dissolved in 9.5 ml of various solvents, and 0.5 ml of DMSO was added and sonicated for 15
minutes. After sonication, the EDOT monomer was added to the oxidant dispersion and
polymerization was pursued under shaking for 18 h at 70 °C and 50 RPM.

II.1.3. Synthesis of GO/DMSO-doped PEDOT
For the synthesis of GO/DMSO-doped PEDOT, 0.8 g of FeCl3•6H2O anhydrous powder was
dissolved in 9.5 ml of various solvents, and 0.5 ml of DMSO was added and sonicated for 15
minutes. 200 µl of the EDOT monomer was mixed with 3 mg of GO nanosheets via sonication for
1 h. The EDOT/GO mixture was then added to the FeCl3•6H2O solution, sonicated for 30 mins,
and under shaking for 18 h at 70 °C and 50 RPM as mentioned previously. Polymerization
conditions are labeled in Table 2.1.

The polymerization reaction resulted in dark blue solutions with solid black particles
suspended in the solution for each PEDOT composition. To obtain the PEDOT particles, the
solutions were washed repeatedly with methanol/H2O (1:1 vol ratio) until the solution in which
the particles resided appeared clear. The solution/particle mixtures were then left to dry on
polytetrafluoroethylene (PTFE) dishes in a 60 °C in vacuum oven.

Table 2.1. Polymerization conditions for each PEDOT type synthesized and studied.
PEDOT types

Solvents
H2O

Ethanol

Methanol

50/50 H20/ EtOH

50/50 H2O/ MeOH

50/50 EtOH/ MeOH

Pure PEDOT

DMSO-doped
PEDOT

Polymerized at 70 °C and 50 RPM for 18 h.

GO/DMSOdoped
PEDOT

44

II.2. Characterization of PEDOT nanoparticles
II.2.1. Reaction yield
Reaction yield was gravimetrically determined by recording the mass of dried PEDOT
powders. The percent yield of the dried PEDOT powders was calculated by dividing the mass of
the PEDOT by 266 mg (the amount of EDOT added).

II.2.2. Surface morphology and elemental composition
The morphology and elemental composition of different PEDOT powders were determined
through Scanning Electron Microscopy (SEM) and Energy Dispersive Spectroscopy (EDS). A
Tescan MIRA3 FEG SEM equipped with Energy-dispersive X-ray spectroscopy (EDAX) Octane
Elite EDS detector was used for imaging and EDS analysis. For SEM imaging, a 5 kV high tension,
a beam intensity of 5 and a working distance of 10 mm were used. For EDS analysis, high tension
was increased to 12 kV and beam intensity was at maximum of 20 for better count rate. The sample
working distance was at eucentric height of 15 mm. Total collection time for each spectrum was
50 live seconds and the amplification time was 0.96.

II.2.3. Chemical composition
The surface chemical composition of the PEDOT nanopowders was analyzed using X-ray
Photoelectron Spectroscopy (XPS). A Kratos Axis Ultra spectrometer with a monochromatized Al
K𝛼 X-ray source (photon energy: 1486.6 eV) was used. The operation power was set at 112 W
with emission at 8 mA and anode high tension at 14 kV. An electron-based charge neutralizer was
turned on to compensate surface charging during spectrum collection. Pass energy at 160 eV and
20 eV were used for surgery scan and core scan, respectively. The samples powders were
compressed with stainless steel spatula to make a flat surface on a conductive copper tape to cover
an area of at least 2x2 mm2. The high-resolution spectra were curve-fitted using the software
provided by the manufacturer.

II.2.4. Ultramorphology using TEM-EDS
A Thermo Fisher Scientific Talos F200X G2 S/TEM was used for TEM and STEM imaging
at accelerating voltage of 200kV. An integrated EDS system is Super-X window-less detector
consists of four equal crystals with an active area of 4 × 30 mm2 and a solid angle of 0.9 srad,
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detecting all elements down to and including boron. The powder samples were ground fist in a
mortar then ultra-sonicated in a beaker with distilled water for 1 minute. Use a pipette or eye
dropper to transfer a few droplets onto a 400-mesh copper grid with lacey carbon support film and
let it try in air. A Gatan One View bottom mount camera was used for TEM imaging. EDS
elemental mapping was performed in STEM mode.

II.2.5. Crystallography analysis
X-ray Diffraction (XRD) was used to measure the crystallinity of the nanoparticles. Samples
were mounted on a Boron-doped silicon P-type zero background diffraction plate and analyzed
with a Bruker D2 Phaser diffractometer using CuKα radiation (λ=1.54184 Å) at 300.0 Watts (30
kV, 10.0 mA). The D2 Phaser uses Bragg-Brentano geometry with a fixed linear (position
sensitive) LYNXEYE 1D strip detector/counter. An incident (primary) beam axial soller slit (2.5
°), divergence slit (1.0 mm), air scatter screen (3 mm) were used. Diffracted (secondary) beam
axial soller slit (2.5 °) and a Ni Kβ filter were also used. Scan parameters include a 5-90 °2θ scan
range, step size of 0.0080 °2θ, and a count time of 0.5 s per step.

II.2.6. Optical properties of PEDOT
Ultraviolet–visible absorbance spectrum of PEDOT particles in suspension was recorded
using a SpectraMax® Plus 384 microplate spectrophotometer, (Molecular Devices, San Jose, CA).
Different PEDOT particles (5 mg) were dispersed in methanol and read at an absorbance range of
300 to 1000 nm on a 96-well plate. Optical properties provide fundamental understanding of the
basic electron structure of the material. The π-π* conjugation in the polymers is implied by their
color and their electronic spectra; thus UV–Vis spectroscopy can be utilized to probe electronic
processes that occur in the polymer during doping.138

II.3. Cytocompatibility assay
II.3.1. Human bone marrow stem cells (BMSCs) culture
Human bone marrow stem cells (BMSCs) derived from bone marrow (Sciencell Research
Laboratories, Carlsbad, CA) were cultured in Mesenchymal Stem Cell Medium (MSCM)
completed with 1% mesenchymal stem cell growth supplement (MSCGS), and 1%
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penicillin/streptomycin solution (all from Research Laboratories, Carlsbad, CA). BMSCs were
incubated at 37 °C and 5% CO2 in a humidified atmosphere. The medium was changed three times
a week. When the cultures reached 90%, the cells were detached from the flasks using a 0.05%
trypsin-0.1% EDTA solution, washed twice, and resuspended in MSCM-supplemented medium.
Cells were then used to seed the biomaterials under study.

II.3.2. BMSCs attachment
PEDOT powders were first pressed into pellets and sterilized using 70% ethanol. BMSCs
(0.05x106 cells/well) were seeded on pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped
PEDOT pellets for 6, 24, 48, and 96 h in 24-well plate. At each time point, BMSCs were fixed
with 4% paraformaldehyde for 15 mins, washed three times using PBS (1x), and stained with 4’,6diamidino-2-phenylindole (DAPI) fluorescent DNA stain (1µg/ml). Cells were then viewed under
an inverted fluorescence microscope (Etaluma, San Diego, CA) with blue fluorescence optics to
visualize cells adhesion.

II.3.3. Cytotoxicity assay
Cytotoxicity

was

performed

using

MTT

test

(3-(4,5-Dimethylthiazol-2-yl)-2,5-

Diphenyltetrazolium Bromide) (MilliporeSigma, St Louis, MO) which has shown to be reliable
and sensitive test for studying cellular growth and viability.134 Cytotoxicity was rated based on cell
viability relative to controls (cells cultured in completed DMEM/F-12 medium). Cells were plated
in a 96-well plate at a density of 0.02x106 cells/well for 24 h prior to treatments. Two different
culturing methods were performed to study PEDOT nanopowders cytotoxicity (Figure 2.2).

A.

B.

Figure 2.2. Schematic of the Cytotoxicity Tests performed on PEDOT nanoparticles on BMSCs.
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1) Direct contact test allows for physical interaction of BMSCs and the different PEDOT
formulations (Figure 2.2-A). BMSCs were cultured in direct contact with increasing
concentrations of pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped PEDOT
nanoparticles (0, 0.1, 0.3. 0.5, 1, 2, and 4 mg/well). PEDOT powders were sterilized using 70%
ethanol and added to cells and cultured for 16 and 24 h.

2) Extract test allows for the interaction of any leachable byproducts (from the
polymerization reaction or the degradation of the PEDOT nanopowders) to interact with BMSCs
in culture without direct contact with the PEDOT powders (Figure 2.2-B). BMSCs were cultured
with released by-products from different PEDOT nanoparticles. PEDOT, DMSO-doped PEDOT,
GO/DMSO-doped PEDOT nanoparticles (40 mg) were soaked in non-completed Dulbecco's
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) media (1000 µL) for 48h at 37 ℃.
Supernatants were harvested, sterilized and incremental concentrations of 0, 1, 2.5, 5, 10 and 20
mg/mL were prepared with completed DMEM/F-12 medium. Culture medium was removed and
the cells were exposed to 150 μl of test compounds diluted in completed DMEM/F-12 at different
concentrations and incubated for 16 and 24 h.

II.3.4. Proliferation assay
Metabolic proliferation was performed using MTT test (MilliporeSigma, St Louis, MO) which
measures the ability of the mitochondrial succinate-tetrazolium reductase to convert the yellow
compound MTT into a blue formazan dye. The amount of dye produced is proportional to the
number of live metabolically active cells. Cells were plated in a 96-well plate at a density of
0.02x106 cells/well for 24 h prior to treatments. Direct contact test as well as extract test were
performed to study the effect of PEDOT nanopowders on BMSCs proliferation and metabolic
activity, as described in II.3.3., for up to 120 h.

II.3.5. MTT test
Immediately following each culture period, the medium (and PEDOT powders if any) were
removed and MTT solution (5 mg/ml MTT in PBS) together with fresh culture medium at an
amount equal to 10% was added to each well. Cells were incubated in the dark for 3 h after which
MTT was removed and the formazan crystals were dissolved in 100 µl of DMSO solution. The
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optical density was read at 570 nm using a SpectraMax® Plus 384 microplate spectrophotometer
(Molecular Devices, San Jose, CA). The MTT test determines cell metabolic activity by measuring
the ability of the mitochondrial succinate-tetrazolium reductase to convert the yellow compound
MTT into a blue formazan dye. The amount of dye produced was proportional to the number of
live metabolically active cells. Each experiment was repeated 3 times.

II.4. Scaffold fabrication
II.4.1. PCL- [GO/DMSO-doped PEDOT] composites synthesis
PCL- [GO/DMSO-doped PEDOT] composites were fabricated using solvent casting method
(Figure 2.3). 0.5g of PCL polymer was dissolved in 5 ml of chloroform (Fisher Bioreagents,
Pittsburgh, PA) for 1 hour to create a 10% solution of PCL. GO/DMSO-doped PEDOT
nanopowders at 5, 10 and 20% weight ratio were mixed with the PCL solution overnight under
vigorous stirring. Pure PCL was used as control. The homogenous solutions were then centrifuged
at 13,200 rpm for 1 min. The black supernatants were cast onto polytetraﬂuoroethylene (PTFE)
plates and dried at room temperature. Resultant PCL-[GO/DMSO-doped PEDOT] composites
were loaded into the Axo-A3 3D bioprinter (Figure 2.4-A, D) (Axolotl Bio, Turkey).

10% PCL in
chloroform

Centrifuge at 13,200
rpm for 1 min

Figure 2.3. Fabrication of PCL-[GO/DMSO-doped] PEDOT composites.

49

II.4.2. PCL-[GO/DMSO-doped PEDOT] 3D scaffolds fabrication
PCL-[GO/DMSO-doped PEDOT] 3D scaffolds were printed using novel 3D electrowriting
technology. Composites were loaded into a stainless-steel cartridge with a 0.2-micron brass nozzle
(Figure 2.4-B). The cartridge was heated to 90℃ for 15 minutes to allow enough time for the
polymer to melt. Two electrodes were connected to the high voltage power supply. The positive
end electrode was connected to the printhead and the negative end electrode was connected to the
print bed, enabling an electrical field between the two components (Figure 2.4-A, C). The MEW
printhead has an electrical heating system to control the temperature, and a pneumatically
regulated feeding system to control the exerted pressure (Figure 2.4-C). The printhead moves
along the X- and Y-axis, while the print bed moves along the Z-axis. Using CAD software, a
predefined cylindrical shape was designed, sliced using Slic3r software and a G-code file was
obtained for the printer to read.

A.

C.
D.

B.

Figure 2.4. Experimental setup of A) the Axo-A3 3D Bioprinter used for the melt-electrowriting,
B) stainless-steel cartilage and nozzle, C) MEW printhead and positive electrode attachment, D)
different printheads.
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II.4.3. Printability study of PCL-[GO/DMSO-doped PEDOT]
The MEW parameters were optimized, and printing was conducted at room temperature with
a voltage of 5kV, a pressure of 10 psi, and a distance of 5 mm (from the nozzle to collector).
Scaffolds were imaged after printing with stereomicroscope and scanning electron microscopy
(Tescan MIRA3 FEG SEM). Imaging was applied to comparatively analyze scaffolds printed
using different parameters. ImageJ (NIH) was used to analyze cross-sectional SEM images to
determine average pore size and filament diameter.

II.5. Statistical Analysis
The statistical analysis was performed using student’s t-test and one-way analysis of variance
(ANOVA) using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Differences are
considered significant as p < 0.05 (*). All values are expressed as the mean ± standard deviation.
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CHAPTER III

RESULTS
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III.1. Characterization of PEDOT nanoparticles
III.1.1. PEDOT polymerization
Initial experiments for determining the optimal polymerization conditions for PEDOT
began by investigating the temperature, time, and mixing rate. During these preliminary tests, pure
PEDOT mixed in H2O was tested. Qualitative analysis revealed pure PEDOT at a temperature of
70°C and a mixing rate of 50 rpm could be synthesized in 30 minutes (Figure 3.1-A). The same
experiment was tested with the addition of 0.5 ml of DMSO. After 30 minutes of mixing at the
same temperature and mixing rate, there was no change in solution color, indicating that
polymerization was not occurring (Figure 3.1-B). Mixing was left to continue at the same
conditions and the solution was observed every 5 minutes to determine if there was any change in
color. At the 18-hour mark, sufficient color change occurred indicating successful polymerization
of DMSO-doped PEDOT in H2O. To further investigate the optimal polymerization conditions,
pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped PEDOT were tested in various
solvents at a temperature of 70°C, a mixing rate of 50 rpm, and a time of 18 hours.

TEM and EDS analysis was performed as well to confirm that PEDOT had in fact
polymerized. Also in Figure 3.1, TEM images show the morphology and size of PEDOT particles.
These images show that the size of the PEDOT particles are approximately 50 -100 nm. The EDS
scan identified the presence of sulfur (S), chlorine (Cl), and iron (Fe) in the composition of the
particles. This suggests that polymerization of PEDOT properly occurred as each element resides
in the PEDOT chain.
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A.

B.

Figure 3.1. A) Pure PEDOT mixed in H2O at 70°C and 50 rpm for 30 mins. Black PEDOT
particles suspended in a dark blue solution B) EDOT-DMSO/ H2O mixture at 70°C and 50 rpm
after 30 mins. Orangish-yellow solution indicting that polymerization is not occurring. TEM
images show the size and morphology of the PEDOT particles. EDS spectra identifies the elements
within the particles.

III.1.2. Reaction yield
Quantitative analysis was performed on different PEDOT/ solvent experiments by
extracting the synthesized particles and obtaining their mass. The mass of the pure PEDOT,
DMSO-doped PEDOT, and GO/DMSO-doped PEDOT nanocomposites showed variation
depending on the solvent used for the polymerization process. As shown in Figure 3.2, PEDOT
composites that were synthesized in a solvent containing H2O yielded a higher mass than those
that were polymerized in EtOH or MeOH. Additionally, the reaction yield showed that the
polymerization of pure PEDOT yielded higher masses than DMSO-doped PEDOT and
GO/DMSO-doped PEDOT.
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Figure 3.2. The yield of PEDOT particles in mass for various polymerization conditions. Solvents
including H2O yielded in higher mass when compared to pure MeOH, EtOH and MeOH/EtOH (n
= 3).

During polymerization, 200 µl of EDOT monomer was used and with a density of 1.331
g/ml, thus the mass of EDOT can be calculated to 266 mg. Knowing this, the percent yield can be
calculated for each PEDOT reaction. As seen in Table 3.1, the percent yield for PEDOT
synthesized in the H2O/EtOH solvent was highest among all other solvents, with pure PEDOT
representing the highest yield at 17.8%. Solvents H2O and H2O/MeOH showed the next highest
percent yield respectively, again confirming that the presence of H2O during polymerization
results in a higher reaction yield. These results helped define the best polymerization conditions
for yielding the highest mass (Table 3.2).
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Table 3.1. The calculated percent yield of synthesized PEDOT nanoparticles in each solvent.
PEDOT solution/

H2O/

EtOH/

MeOH

MeOH

17.8% ±0.04

8.7% ±0.04

1.3% ±0.02

0.2% ±0

15.0% ±0.05

6.7% ±0.03

0.5% ±0.01

0.2% ±0

14.6% ±0.03

2.5% ±0.02

1.4% ±0.02

H2O

EtOH

MeOH

H2O/ EtOH

Pure PEDOT

14.4% ±0.06

1.6% ±0.02

1.1% ±0.01

DMSO-doped PEDOT

11.3% ±0.06

2.1% ±0.03

7.7% ±0.03

0.9% ±0.01

Solvent type

GO/DMSO-doped
PEDOT

Table 3.2. The effectiveness of each condition based on the amount mass yielded after
polymerization. PEDOT dissolved in H2O/EtOH was the most consistent for yielding with high
mass for all types of PEDOT studied.
PEDOT / Solvent type

H 2O

EtOH

MeOH

H2O/ EtOH

H2O/ MeOH

EtOH/ MeOH

Pure PEDOT

+++

++

-

+++

++

-

DMSO-doped PEDOT

+++

-

-

+++

+

-

GO/DMSO-doped PEDOT

++

-

-

+++

+

-

The different solvents also influenced the overall appearance of the PEDOT particles. As
seen in Figure 3.3, PEDOT particle form fell into one of three categories: hard pellets, soft
powders, and thin sheets. The results indicated that specific solvents favored a particular form.
For instance, PEDOT synthesized in H2O favored the formation of hard pellets, while PEDOT
synthesized in EtOH and MeOH favored the formation of soft powders and thin sheets,
respectively. As for the 50:50 mixture solvents, the appearance of the powders would vary.
PEDOT in the H2O/EtOH solvent typically fell in the hard pellet category while PEDOT
polymerized in the H2O/MeOH solvent would form thin sheets.
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A.

C.

B.

Figure 3.3. Different appearance categories of PEDOT particles. A) Hard pellets B) Soft powder
C) Thin sheets.

The yield of PEDOT polymerized in the EtOH/MeOH solvent was too miniscule to analyze.
The polymerization conditions of PEDOT particles synthsized in EtOH were studied further
because of their soft powdery form. Different washing protocols and extendeded incubation time
were studied. It was determined that when the incubation time was extended, the average mass as
well as the reaction yield increased (Table 3.3).

Table 3.3. The reaction yeild of PEDOT particles synthesized in EtOH with an exnteded
incubation time.
PEDOT Type

Average mass (mg)

Percent yield

Pure PEDOT

132.7 ±3.2

49.9% ±0.01

DMSO-doped PEDOT

43.1 ±14.2

16.2% ±0.05

GO/DMSO-doped PEDOT

47.3 ±14.1

17.8% ±0.05

III.1.3. Surface morphology and elemental composition
The morphologies of pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped
PEDOT polymerized in H2O/EtOH and EtOH solvents were investigated to determine the effects
DMSO and GO had on the morphology of PEDOT. As shown in Figure 3.4, SEM analysis revealed
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the solvent has an effect on the morphology of the PEDOT nanocomposites. PEDOT polymerize
in the H2O/EtOH solvent showed a rod-like morphology while the EtOH solvent yielded particles
with a smooth globular morphology. Additionally, the incorporation of DMSO and GO into the
polymer system influenced the morphology. In DMSO-doped particles, the morphologies
appeared more compact when compared to the morphologies in pure PEDOT. In GO/DMSOdoped PEDOT, the morphologies appeared compact while also consisting of a more lamellar
structure. The solvent also influenced the particle size. Qualitative analysis of SEM
photomicrographs revealed PEDOT nanocompsites of a much smaller size when synthesize in
H2O/EtOH when compared to PEDOT synthezied in EtOH. It can be estimated that the size of the
particles in H2O/EtOH are 100-200 nm while the particles in EtOH are closer to the micron level.

Figure 3.4. The effect of DMSO and GO on the morphology of PEDOT. SEM photomicrographs
of pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped PEDOT showing a rod-like
morphology, when H2O/EtOH (50:50) was used (scale bar 200 nm) as solvent and a globular
morphology when EtOH was the solvent (scale bar 1 µm).
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morphological

investigation

was

performed

DMSO-doped

PEDOT

nanocomposites to distinguish the influence different solvents had on the particles of the same
PEDOT type. As shown in Figure 3.5, the morphologies again varied depending on the solvent
used. DMSO-doped PEDOT in H2O revealed a more compact coral-like morphology, whereas
DMSO-doped PEDOT in MeOH showed a rough globular/ thin thread mixture morphology and
DMSO-doped PEDOT in H2O/MeOH illustrated a highly compact rough globular morpholgy.

Figure 3.5. The effect of the solvent on DMSO-doped PEDOT morphology. SEM
photomicrographs depict unique morphologies for A) H2O, B) EtOH, C) MeOH, D) H2O/EtOH
E) H2O/MeOH.

Energy Dispersive Spectroscopy (EDS) spectrums, shown in Figure 3.6, identified the
presence of carbon (C), oxygen (O), sulfur (S), chlorine (Cl), and small traces of iron (Fe) on the
surface of DMSO-doped PEDOT nanocomposites. The high levels of C, O, and S shown in the
spectrums indicated successful polymerization of DMSO-doped PEDOT as the chemical structure
of PEDOT contains these elements (Figure 1.11 in introduction). The elemental atomic ratio was
determined for these elements for each sample, indicating the percentage of each atom relative to
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1 µm

Further

the total number of atoms. Table 3.4 shows the atomic percentage for the elements listed above for
the DMSO-doped PEDOT samples. Each sample tested revealed an adequate amount of C, O, and
S indicating that polymerization occurred regardless of the solvent chosen. Interestingly, PEDOT
samples polymerized in EtOH showed no amount of Cl in the structure. This may indicate that
whilst polymerization was occurring, the DMSO competed with the Cl of the FeCl3 oxidant and
overtook the counteranion role during the doping process, which the Cl usually fills.

A.

B.

C.

D.

E.

Figure 3.6. EDS spectrums of DMSO-doped PEDOT in various solvents. A) H2O B) EtOH C)
MeOH D) H2O/EtOH E) H2O/MeOH. Each spectrum indicated the presence of important elements
seen in PEDOT, including carbon (C), oxygen (O), and sulfur (S).
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Table 3.4. Elemental atomic percentage of elements for each sample of DMSO-doped PEDOT by
EDS analysis. ND, not detectable.
Solvent

Elemental atomic %
C

O

S

Cl

Fe

H2O

57.9

20.9

16.5

4.3

0.3

EtOH

52.4

8.3

38.6

ND

0.4

MeOH

62.9

22.8

12.8

1.1

ND

H2O/EtOH

30.5

34.3

10.9

6.5

17.5

H2O/MeOH

43.6

21

17.5

12.5

5.2

EDS analysis was further studied in each PEDOT type synthesized in H2O to understand
the effect DMSO and GO had on the elemental composition of the PEDOT. As shown in Table
3.5, the same elements were found in each of the PEDOT samples. This analysis confirmed the
presence of DMSO and GO by the increased sulfur (S) and carbon (C) levels in the DMSO-doped
PEDOT and the GO/DMSO-doped PEDOT composite, respectively.

Table 3.5. Elemental atomic percentage of C, O, S, Cl, and Fe in pure PEDOT, DMSO-doped
PEDOT, and GO/DMSO-doped PEDOT polymerized in H2O.

PEDOT in H2O

Elemental atomic %
C

O

S

Cl

Fe

Pure PEDOT

62.99

25.29

10.19

0.93

0.79

DMSO-doped PEDOT

62.33

18.08

15.9

0.68

3

GO/DMSO-doped PEDOT

73.72

18.82

5.5

2.12

0.66

III.1.4. Chemical composition
The chemical bonding of various PEDOT composites polymerized in EtOH was verified
using X-ray photoelectron spectroscopy (XPS). The full survey scan spectra are shown in Figure
3.7. XPS identified carbon (C), oxygen (O), sulfur (S), chlorine (Cl), and iron (Fe) as the
constituents of the three different PEDOT nanocomposites. The S2p and S2s peaks at 166.5 and
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220.5 eV are attributable to the sulfur in PEDOT.137 Therefore, all the PEDOT formulations
contained sulfur bonds. C1s observed between 284-286 eV and the O1s between peaks 529-532
eV are markers of successful polymerization of PEDOT. The Cl2p and Cl2s peaks also illustrate
the Cl counteranion from the FeCl3 oxidant, indicating that FeCl3 is an effective oxidant for the
oxidative polymerization of EDOT. These two peaks noticeably decrease with the addition of
DMSO and GO, suggesting that the secondary dopant are compete with the FeCl3 oxidant during
the doping process.

Pure PEDOT

O 1s

DMSO-doped PEDOT

1200

1000

800

600

400

S 2s
Cl 2p
S 2p

Cl 2s

Fe 2s

Fe 2p

O KLL

C 1s

GO/DMSO-doped PEDOT

200

0

Binding Energy (eV)

Figure 3.7. XPS full spectra of Pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped
PEDOT.
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The ratio between Cl and S changes between the separate PEDOT composites. As shown
in Table 3.6, the ratio of Cl/S decreases from 0.46 for pure PEDOT to 0.27 and 0.33 for DMSOdoped PEDOT and GO/DMSO-doped PEDOT, respectively. This make sense as increased
amounts of sulfur was added to the PEDOT from the incorporation of DMSO. This illustrates the
secondary doping mechanism from the DMSO when added during polymerization. To investigate
possible formation of sulfur groups, the S2p spectra of the PEDOT composites were compared
(Figure 3.8). The doublet XPS peaks with binding energies between 162 and 166 eV are assigned
to the S 2p band of the sulfur atoms in the PEDOT.135 The S2p1/2,3/2 doublet, typical of the sulfur
atom in the thiophene ring, is present at around 163 eV and 165 eV.136
Indeed, there is an increase of sulfur atom in the neutral (S 2p) and the partially oxidized
state (S 2p+) in the DMSO-doped PEDOT 84.2%, when compared to pure PEDOT 73.37% and
GO/DMSO-doped PEDOT 79.23%, where GO is competing with DMSO for secondary doping
(Figure 3.8).

Table 3.6. Ratio of Cl/S of pure PEDOT, DMSO-doped PEDOT, and GO/DMSO-doped PEDOT.
Types

Cl/S

Pure PEDOT

0.46

DMSO-doped PEDOT

0.27

GO/DMSO-doped PEDOT

0.33

The typical PEDOT C1s spectrum contains peaks from three distinct types of carbon
(Figure 3.9). These are (i) C–S in the α-position of PEDOT, (ii) C=C–O in the β-position, and (iii)
C–O–C bonding in the ethylene bridge. Hence, the C1s signal is composed with three different
contributions corresponding to three non-equivalent carbon atoms: C–S (285.2 eV), C=C–O (283.7
eV), and C–O–C (287.3 eV).136 When comparing the spectra of the three separate PEDOT groups,
we appreciate a decrease in the intensity of the C=C–O carbon with GO/DMSO-doped PEDOT.
For the C–S carbon, there is an increase in the GO/DMSO-doped PEDOT when compared to pure
PEDOT and DMSO-doped PEDOT. For the C–O–C carbon, pure PEDOT shows the highest
intensity when compared to DMSO-doped PEDOT and GO/DMSO-doped PEDOT. Additionally,
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an asymmetrical peak at about 288 eV was also identified and attributed to the π–π* shake-up
transition and positively polarized or charged carbon. There is an increase of the C shake-up
intensity in the GO/DMSO-doped PEDOT 8.49, compared to DMSO-doped PEDOT 7.85 and pure
PEDOT 1.26.
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Figure 3.8. The XPS core S2p spectra of pure PEDOT, DMSO-doped PEDOT, GO/DMSO-doped
PEDOT.
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Figure 3.9. The XPS core C1s spectra of pure PEDOT, DMSO-doped PEDOT, GO/DMSO-doped
PEDOT.
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Figure 3.10 presents O1s spectra for the separate PEDOT types. The characteristic peak of
the oxygen in the dioxy-ring appears at 532 eV.136 However, deconvolution of the curves results
in three additional small contributions in the spectra. The first is at approximately 530 eV and the
other peak appears at 532 eV. The third peak is the smallest peak arising at 529 eV and may be
attributed to further oxidation of the PEDOT. Figure 3.11 shows the Cl2p core spectra, indicating
the presence of Cl as a counteranion from the FeCl3 oxidant. When comparing the three PEDOTs,
it can be noticed that the Cl2p1/2, 3/2 peaks were much more intense in pure PEDOT, than in DMSOdoped PEDOT or GO/DMSO-doped PEDOT. The atomic percentage of Cl2p3/2 for pure PEDOT
was 44.11%, while DMSO-doped PEDOT was 28.80% and GO/DMSO-doped PEDOT was
31.94%. This further suggests that the incorporation of DMSO and GO during polymerization
compete with the Cl from the oxidant during doping, ultimately leading to less Cl being bound to
the polymer system. In addition, the Cl peaks in pure PEDOT have a higher binding energy than
both the DMSO- and GO- doped PEDOTs, suggesting that the Cl in the pure PEDOT is more
tightly bound within the polymer system, as no other dopants are competing with it during
polymerization.
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Figure 3.10. The XPS core O1s spectra of pure PEDOT, DMSO-doped PEDOT, GO/DMSOdoped PEDOT.
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Figure 3.11. The XPS core Cl2p spectra of pure PEDOT, DMSO-doped PEDOT, GO/DMSOdoped PEDOT.
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III.1.5. Crystallography analysis
X-ray diffraction (XRD) patterns of PEDOTs are shown in Figure 3.12. All the polymers
show characteristic peak at nearly 2θ ~ 26°, which can be attributed to the interchain planar ring
stacking.133 A comparison between separate PEDOTs each with the diffraction peak of 2θ ~ 26°
indicates that the crystallinity does not vary with the addition of DMSO and GO and thus they do

Intensity (counts)

not contribute to a change of the crystal structure for PEDOT.

Degrees (2Ɵ)

Figure 3. 12. XRD patterns of pure PEDOT, DMSO-doped PEDOT, GO/DMSO-doped PEDOT.

III.1.6. Optical properties of PEDOT
Figure 3.13 shows the UV-Vis absorption spectra of pure PEDOT and GO/DMSO-doped
PEDOT polymerized in H2O, EtOH, and H2O/EtOH solvents. Regardless of the solvent, all UVVis absorption spectra exhibit the same general shape with relatively sharp absorptions in the UV
at 300 – 400 nm and an intense, broad absorption at longer wavelengths. The peaks at
approximately 700 – 900 can be ascribed to the π-π* transitions of thiophene ring.139 These features
are typically seen in the partially doped (oxidized) state of PEDOT and thus indicate that the
PEDOT samples are doped, regardless of the solvent used. To further investigate the formation of
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polarons and/or bipolarons within PEDOT, studies indicate that the wavelength must be increased
past 1000 nm.133,140
6
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Figure 3.13. UV-vis spectra of pure PEDOT and GO/DMSO-doped PEDOT polymerized in
H2O, EtOH, and H2O/EtOH solvents.

III.2. Cytocompatibility assay
III.2.1. BMSCs attachment
BMSCs cultured in direct contact with PEDOT and stained with DAPI fluorescence stain
show cellular adhesion to the PEDOT. As shown in Figure 3.14, BMSCs can be seen on the surface
of the various PEDOT powders. Quantitative analysis was performed on DAPI images to
determine the number of cells attached to PEDOT as shown in Figure 3.15. There was no
significant difference between the number of cells that adhered on different PEDOT types, when
compare to cells cultured in a tissue culture plate (TC plate).
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B.

A.

100 µm

100 µm
D.

C.

100 µm

100 µm

Figure 3.14. BMSCs adhesion on PEDOT particles. BMSCs were cultured in direct contact with
PEDOT particles for up to 96 hours and stained using DAPI. A) BMSCs on TC plate with no
PEDOT B) BMSCs with pure PEDOT C) BMSCs with DMSO-doped PEDOT D) BMSCs with
GO/DMSO-doped PEDOT.
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Figure 3.15. Semi-quantitative analysis of BMSCs adhesion on PEDOT particles.

III.2.2. Cytotoxicity assay
Two separate tests were run to determine the cytotoxicity of PEDOT nanoparticles on
BMSCs at 16- and 24- h. The first test was to investigate the cytotoxicity of each PEDOT type
when in direct contact with BMSCs. Figure 3.16 illustrates this test by showing BMSCs cultured
in a 96-well plate, in direct contact with various concentrations of each PEDOT type.
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Figure 3.16. Bone marrow stem cells cultured in direct contact with various masses of A) pure
PEDOT, (B) DMSO-doped PEDOT, (C) GO/DMSO-doped PEDOT particles for 120h.

Direct contact test allows for the physical interaction of BMSCs and the different PEDOT
formulations. As shown in Figure 3.17, the PEDOT nanoparticles demonstrated low cytotoxic
effects on the BMSCs when compared to the control. Interestingly, at 16 h, pure PEDOT particles
at a concentration of 2 mg, showed a significant increase in cell viability. Similarly, at 16 h
GO/DMSO-doped PEDOT particles at a concentration of 0.3 mg show a significant increase in
cell viability. When looking at the 24 h time point, there was no significant effect on the viability
of BMSCs for each PEDOT type at various concentrations. This data suggests that the various
PEDOT composites do not have a cytotoxic effect when in direct contact with BMSCs.
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Figure 3.17. The cell viability of BMSCs when cultured in various amounts of pure PEDOT,
DMSO-doped PEDOT, GO/DMSO-doped PEDOT particles for A)16- and B) 24 h.

The second test set out to distinguish the cytotoxicity of any leachable byproducts of the
PEDOT nanoparticles from the polymerization reaction or the degradation. As shown in Figure
3.18, the PEDOT soaked extract medium at various concentrations showed a low cytotoxic effect
on the BMSCs when compared to the control. These results suggest that there are no harmful
byproducts from the polymerization reaction or from the degradation of PEDOT, DMSO, or GO.
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Figure 3.18. The cell viability of BMSCs when cultured in various concentrations of pure PEDOT,
DMSO-doped PEDOT, GO/DMSO-doped PEDOT soaked extract medium for A)16- and B) 24 h.

III.2.3. Proliferation assay
A similar set of experiments were performed to study the proliferation of BMSCs when
cultured in direct contact and in PEDOT soaked extract in medium. As shown in Figure 3.19, pure
PEDOT and GO/DMSO-doped PEDOT showed no significant effect on the proliferation of
BMSCs for up to 120 h. In the case of DMSO-doped PEDOT, there is a significant decrease in the
proliferation of BMSCs for a concentration of 2 mg at 120 h. This thus suggests that a
concentration of 2 mg of DMSO-doped PEDOT may be too high for proper cellar division to occur
for BMSCs. Additionally, although not significant, there is a common trend that can be seen in 0.5
mg of pure PEDOT and 0.1-0.5 mg of GO/DMSO-doped PEDOT where the proliferation of
BMSCs begins to increase from the 72-h point to the 120-h point, indicating that cells maybe be
recovering. This data further suggests that various PEDOT composites do not influence the
metabolic activity of BMSCs when cultured in direct contact.
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A.

B.

C.

Figure 3.19. Cellular proliferation of BMSCs when cultured in direct contact with various
concentrations of A) pure PEDOT, B) DMSO-doped PEDOT, and C) GO/DMSO-doped PEDOT
nanoparticles for up to 120 h.
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As seen in Figure 3.20, various types of PEDOT extract media, have no significant effect
in the proliferation of BMSCs. For pure PEDOT extract, it shows a similar trend for most
concentrations from 24 to 120 h. The concentration of 20 mg/ml, however, shows a slight decrease
in cellular proliferation at 120 h. This may suggest that 20 mg/ml is too high of a concentration for
BMSCs to properly divide in. As for DMSO – and GO/DMSO- doped PEDOT, there again is no
significant effect on the proliferation of BMSCs when cultured in these extract medias. Each
concentration shows a steady level of metabolic activity from 24 – 120 h. This data thus
demonstrates that there are no harmful leachable byproducts from the polymerization of PEDOT
or from PEDOT degradation, suggesting that PEDOT would be a proper material to use for invitro cellular studies.
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B.

C.

Figure 3.20. Cellular proliferation of BMSCs when cultured in various concentrations of A) pure
PEDOT, B) DMSO-doped PEDOT, and C) GO/DMSO-doped PEDOT soaked extract medium for
up to 120 h.
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III.3. Scaffold fabrication
III.3.1. PCL- [GO/DMSO-doped PEDOT] composites synthesis
Moving forward, only GO/DMSO-doped PEDOT nanoparticles were studied, as they were
to be used for the fabrication of a PCL-[GO/DMSO-doped PEDOT] scaffold. As shown in Figure
3.21, the creation of PCL-[GO/DMSO-doped PEDOT] composites showed homogeneity for each
concentration. The darkness of the composites increases with the increased amount PEDOT added.
The formed composites were cut up and loaded into the printer for scaffold fabrication.
Pure PCL

PCL + 5% GO/DMSO-doped PEDOT

PCL + 10% GO/DMSO-doped PEDOT PCL + 20% GO/DMSO-doped PEDOT

Figure 3.21. Homogeneous PCL-[GO/DMSO-doped PEDOT] composites created to be later
loaded into the 3D printer for MEW printing.
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III.3.2. PCL-[GO/DMSO-doped PEDOT] 3D scaffolds fabrication
Initial experiments were performed on pure PCL to determine the MEW parameters needed
to print nanofibrous scaffolds. As shown in Figure 3.22, different PCL scaffolds were created to
distinguish the optimal parameters. Preliminary tests first focused on the parameters of nozzle size,
temperature, and applied pressure. After various experiments, it was determined that with a nozzle
size of 0.4mm, a processing temperature of 150°C, and a pressure of 10 psi, nanofibers could be
formed. With these parameters set, the parameters of voltage, printhead speed, and nozzle tip
distance, were focused on to further optimize the printing process. Initially, the voltage of 3kV
was tested which yielded aligned microfibers on a rigid scaffold. These settings were not ideal as
we were aiming to yield nanofibers and a more flexible scaffold, as this would more closely mimic
the native ECM of bone. Thus, the voltage was increased to 4 kV, to potentially create a thinner
fiber jet. Voltages of 4kV resulted in more aligned microfibers in a rigid scaffold. It was not until
voltages were increased to 5 kV, that we obtained thinner fibers.

At a voltage of 5kV, a thinner fiber jet was extruded from the nozzle, resulting in
nanofibrous scaffolds. The increase in the voltage however, accounted for the random alignment
of the fibers on the collector. Therefore, both the distance and speed were reduced to potentially
counteract the whipping of the fibrous jet that occurs due to the increased voltage. The reduction
of speed and distance at the same time however, lead to printing failure as the electrical field
between the nozzle and the tip came too close together, shocking the system and causing for the
printer to be shut off. The lowest distance and speed that could be set for a voltage of 5 kV and get
a completed scaffold was at 5 mm and 50 mm/s, respectively. These parameters yielded a
nanofibrous scaffold with coiled fibers but with still a degree of alignment. This scaffold was also
both flexible and soft. These settings thus indicated the optimal parameters for printing a
nanofibrous PCL scaffold, that could mimic the native ECM of bone (Table 3.7).
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Table 3.7. Parameters and results of 3D pure PCL scaffolds for MEW.
0.4 mm nozzle, processed at 150 °C at 10 psi

Apparatus Parameters
Voltage

Speed

Distance

(kV)

(mm/s)

(mm)

3

40

4

Results

Fibers

Alignment

Texture

5

microfibers

aligned/ straight

rigid/hard

50

5

microfibers

aligned/ straight

rigid/hard

4

40

5

microfibers

failed

rigid/soft

5

50

5

nanofibers

aligned/coiled

flexible/soft

5

40

5

microfibers

failed

flexible/soft

5

30

5

microfibers

failed

rigid/hard

5

50

6

nanofibers

random

rigid/soft

5

40

6

microfibers

random

rigid/hard

5

30

6

nanofibers

failed

flexible/soft

5

50

7

microfibers

random

rigid/hard

5

40

7

microfibers

random

rigid/hard

5

30

7

microfibers

random

rigid/hard
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Figure 3.22. Close up look at various PCL printed scaffolds.

With the optimal parameters determined for a nanofibrous PCL scaffold, PCL[GO/DMSO-doped PEDOT] (PCL-PEDOT) composites were loaded in to the printer to determine
if these parameters held true with the incorporation of PEDOT. Using a nozzle size of 0.4 mm, a
processing temperature of 150°C and a pressure of 10 psi, printing began at a voltage of 5kV, a
speed of 50 mm/s, and a distance of 5 mm. As shown in Figure 3.23, prints occurring at a voltage
5kV resulted in highly aligned microfibrous scaffolds. Therefore, the parameters identified as
optimal for a pure PCL scaffolds do not result in a nanofibrous scaffolds when printing PCLPEDOT scaffolds. Based off the previous results, the voltage was increased to 7 and 8 kV to
attempt to yield nanofibers. Immediately, the increase in voltage yielded finer nanofibers and softer
scaffolds as a result. The parameters of distance and speed were them tampered with to determine
the optimal settings for aligned nanofibers. Parameters consisting of 8 kV, at 50 mm/s and a
distance of 10 or 11 mm resulted in aligned/ coiled nanofibers and flexible/soft scaffolds. Further
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investigation is needed to determine if parameters can be enhanced even further to increase fiber
alignment within the scaffolds.
7 mm

5 mm
Both at 50 mm/s

5 kV

9 mm

7 mm

11 mm

50 mm/s

40 mm/s

11 mm

10 mm

9 mm

7 kV

50 mm/s

8 kV

30 mm/s

30 mm/s
11 mm

30 mm/s
10 mm

Both at 50 mm/s

Figure 3.23. PCL-[GO/DMSO-doped PEDOT] scaffolds printed with various parameters.
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CHAPTER IV

DISCUSSION
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IV.1. Introduction
Bone harnesses the unique ability to intrinsically regenerate itself after a fracture. However,
in the case of significant bone loss or poor vascularization, the biological process can sometimes
fail leading to insufficient healing or nonunions.22 In the case of long bone fractures, those related
to the tibia in a high energy setting are among the most common.3 These fractures are also
susceptible to a variety of complications such as significant bone loss and delayed or nonunions.4
Currently there is no standard procedure to address significant bone defects of the tibia and current
treatment options present potential undesired effects to the patient.7

Advancements in bone tissue engineering and regenerative medicine are currently on the
forefront for resolving this problem by utilizing a triad of osteocompetent cells, osteoconductive
scaffolds, and bioactive stimuli to facilitate proper bone regeneration in difficult to heal bone
defects.10 Current strategies are focused on fabricating new and inexpensive biocompatible and
bioactive scaffolding materials that can support stem cell maturation and mimic the native bone
matrix in the body. In the recent years, the biomimetic approach has generated much interest and
has proven to be more useful than conventional methods by reason of the possibility of developing
natural and synthetic bone graft substitutes that mimic the composition, structure, and biological
characteristics of natural bone tissue.12 Ultimately, these materials play a significant role in bone
tissue engineering.

Electrical stimulation therapy aims to exploit the endogenous electrical field the human
body generates after injury to enhance cellular responses and promote bone regeneration.36 It has
been known for some time that an electrical current can enhance wound healing, nerve
regeneration, muscle contraction, and bone growth.38 To facilitate this process, interest has been
given to highly conductive biomaterials, such as conductive polymers, for their potential to act as
an electroconductive substrate to enhance cellular behavior during electrical stimulation therapy
practices.61 In this study, we developed a novel conductive biomaterial and used 3D meltelectrowriting

technologies to print a nanofibrous scaffold for bone tissue engineering

applications.

86

IV.2. Preparation and characterization of PEDOT particles
IV.2.1. Polymerization
The conductive polymer PEDOT was synthesized in various forms through oxidative
polymerization to study the optimal conditions required to create a highly conductive biomaterial
to be used in 3D scaffold fabrication. Results showed that pure PEDOT, DMSO-doped PEDOT,
GO/DMSO-doped PEDOT could be synthesized in an EDOT: FeCl3*6H2O ratio of 1:3, yielding
dark black nanoparticles in the form of hard pellets, soft powders, and thin sheets. This process
was achieved in a variety of solvents, each resulting in a different percent yield. PEDOTs that were
synthesized in solvents containing H2O generally resulted in higher yields than those that did not
contain H2O. These H2O synthesized PEDOTs resulted in large hard pellet forms. When
polymerization conditions were changed, namely incubation time, the percent yield of PEDOT
synthesized in EtOH drastically increased, resulting in smaller, soft powders. PEDOT
polymerization studies have demonstrated the use of different solvents in the formation of PEDOT
composites and films is possible, indicating that a variety of solvents can be used to synthesize
PEDOT via oxidative polymerization and/or electrochemical polymerization. To our knowledge,
no study has analyzed the reaction yield of PEDOT polymerized in various solvents which we aim
to offer here. It may be especially useful to understand what solvent to use, base on what you want
to obtain. If larger amounts are wanted, the use of H2O is best. If someone wants PEDOT in the
form of a soft powder, EtOH may be used. Depending on the goal, this study can offer insight to
those who are looking for a specific formulation of PEDOT.

IV.2.2. Morphology and elemental composition
Based off SEM observations, it was apparent that use of different solvents not only had an
effect on the morphology of PEDOT, but on the particle size as well. Each solvent influenced a
unique morphology for the PEDOT as well as a different particle size. As of now, there is no clearcut morphology denoted to PEDOT in the literature, therefore it cannot be determined which
morphology is most ideal. Some studies have referenced the idea that having a more compact
morphology leads to high conductivity, as electrons are available to move through the polymer
chain more easily.133 The homogeneity of the morphologies may also play a role in the overall
conductivity of the material, and thus it may be beneficial to choose a solvent that produces a more
homogenous morphology. In terms of creating a biomaterial, it would stand to reason that a
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smoother morphology, as represented in the PEDOTs synthesized in EtOH, may lead to higher
levels of cellular adhesion, and thus may be an objective for future studies. The addition of DMSO
and GO also played a role in the resulting morphologies leading to more compact particles for
when DMSO was added and more lamellar morphologies for when GO was added, suggesting that
GO nanosheets were incorporated in the PEDOT polymer chain.

The TEM-EDX and EDS observations demonstrated that polymerization was successful
for each solvent studied, not mentioning the EtOH/MeOH solvent. The elements found in typical
PEDOT polymers were present in the TEM results. The incorporation of DMSO showed an
increase in sulfur, further demonstrating that the DMSO was filling its role as a secondary dopant.
On a similar note, the addition of GO indicated an increase in carbon, demonstrating its ability to
compete with FeCl3 and DMSO during the doping process and be incorporated into the PEDOT
polymer system. Ultimately there was no significant differences in the elemental atomic
percentages between the solvents studied. As noticed in Table 3.4, When EtOH was used as a
solvent, sulfur had a much higher atomic percentage, potentially demonstrating that DMSO works
best as a secondary dopant in this solvent. More studies would need to be done to determine if the
solvent effect the rate doping abilities of DMSO or of GO during polymerization.

IV.2.3. XPS, XRD, and UV-vis studies
XPS observations indicated the chemical composition of the PEDOT particles. The survey
scan spectra shown in Figure 3.7 highlights the commonly featured peaks for PEDOT, namely the
S2p and S2s peaks at 166.5 and 220.5 eV, which attribute to the sulfur in the thiophene ring of the
PEDOT. Also, the spectra showed the C1s peak observed between 284 - 286 eV and the O1s peak
between 529 - 532 eV confirming polymerization of PEDOT. The ratio of Cl to S changed with
the incorporation of DMSO and GO, which again confirmed that both DMSO and GO act as a
secondary dopant. This ratio was lowest in DMSO-doped PEDOT which was expected, as the
addition of DMSO should increase the sulfur content if it is properly doped with the PEDOT.
GO/DMSO-doped PEDOT held a ratio of 0.33, which was lower that pure PEDOT, but higher
than DMSO-doped PEDOT, indicating that sulfur binding had increased from the DMSO, but that
the GO was competing with DMSO for secondary doping. This is information is also available in
the increase of sulfur atom in the neutral (S2p) and the partially oxidized state (S2p+) in the
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DMSO-doped PEDOT as well as in the Cl2p spectra. The deconvoluted C1s, S2p, and Cl2p core
spectra all indicate the successful polymerization of PEDOT. The change in peak intensities and
shifts, seen in these core spectra, with the addition of DMSO and GO, indicate that doping levels
are increasing with these two secondary dopants. This eludes to the idea that the conductivities of
the PEDOTs will increase with the incorporation of DMSO and GO.
XRD patterns describe the crystallinity of the PEDOT types as essentially the same. All
PEDOTs showed the characteristic peak at nearly 2θ ~ 26°, which can be attributed to the
interchain planar ring stacking. These results are supported by the literature. It was expected that
the GO/DMSO-doped PEDOT would show a peak referencing the GO within the system, but
analysis proved otherwise. UV-vis analysis was aimed to distinguish the oxidation and general
electron structure of the PEDOT, when synthesized in organic solvents versus inorganic solvents
versus a mixture of organic and inorganic solvents. Each spectrum analyzed demonstrated a
relatively sharp absorption at 300 - 400 nm and other typically peaks at the 700 - 900 region.
Literature denotes these features to the oxidized state of PEDOT, indicating that the samples are
doped. The literature also references a broad absorption at wavelengths longer than 1000 nm.133,140

IV.3. PEDOT’s influence on the cellular behavior of BMSCs
IV.3.1. Cellular attachment
DAPI fluorescent staining observations illustrated BMSC attachment to the PEDOT
composites, when cultured in direct contact for up to 96 h. Cellular adhesion was seen as early as
6 h and was in fact seen at every time point. The incorporation of DMSO had the strongest
influence on the cellular adhesion while pure PEDOT and GO/DMSO-doped PEDOT were similar.
It is important to see that BMSCs are able to adhere on to the powders, as this is an important
parameter for effective biomimetic scaffolds. If the cells are able to adhere to the PEDOT alone,
they may be prepared to adhere to a scaffold made of the same material. This provides context for
future studies on BMSC behavior with PEDOT scaffolds.
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IV.3.2. Cellular viability and proliferation
To ensure that a PEDOT material is safe to for cells to live and grow on, it is important that
it be cultured with BMSCs in in-vitro studies to see how the cell behave in this environment. Our
cell viability experiments ultimately demonstrated that PEDOT is a non-cytotoxic material towards
BMSCs. This indicates that the proper amount of DMSO and GO were implemented in the
PEDOT, as both are known to have cytotoxic effects at high concentrations. The data for BMSCs
cultured in direct contact with pure PEDOT at 2 mg and GO/DMSO-doped PEDOT at 0.3 mg after
16 h, indicate that PEDOT might positively affect the viability of BMSCs. Further experiments
would need to be run to determine if these were optimal concentrations for BMSCs. The cell
viability in the extract test, indicate that there are no harmful byproducts that come from the
polymerization process or from PEDOT degradation. This shows that PEDOT can be a useful
biomaterial to be used in bone regeneration studies.

BMSC proliferation experiments indicated similar results, suggesting that neither direct
contact nor extract media culturing had a significant effect in the metabolic activity of BMSCs.
However, when BMSCs were in direct contact with DMSO-doped PEDOT at a concentration of 2
mg for 120 h, there was a significant decrease in the proliferation of BMSCs. This may suggest
that 2 mg is too high of a concentration for BMSCs to properly live and divide. However, this
trend was not demonstrated in any of the other PEDOT types, indicating that further research
should be done to see what the threshold is for PEDOT concentration. The remaining extract test
again showed no significant effect on the proliferation of BMSCs, indicating that PEDOT allows
for BMSCs to properly proliferate without effecting any metabolic processes. This demonstrates
PEDOT may be an effective biomaterial for bone tissue engineering scaffolds.

IV.4. Fabrication of PCL-[GO/DMSO-doped PEDOT] scaffold
IV.4.1. Melt-electrowriting
PCL is an FDA-approved biodegradable polymer that has been used in various tissue
engineering applications. Its easy processability makes it an ideal polymer to study with a complex
3D printing technique such as melt-electrowriting (MEW). The successful fabrication of PCL
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scaffolds relies on a plethora of parameters that work together. In our experiments, it was found
that increasing the voltage yields in thinner fibrous jets, and thus smaller fibers. However, the
increased voltage allows for more whipping instabilities from the fibrous jet, and thus random fiber
alignment. Although the native ECM is not perfectly aligned, it is ideal to have control over
alignment, so proper pore sizes can be fabricated for the specific cells living on them.

By working with the relationship between voltage, distance and collection speed, aligned
nanofibrous scaffolds can be achieved. In this study, the parameters highlighted in Table 3.8,
indicate that a voltage of 5 kV, with a collection speed of 50 mm/s and a nozzle to collector distance
of 5 mm, yield the best results; a well aligned nanofibrous scaffold. The fibers in this scaffold were
also very flexible when compared to others, which is an ideal trait to have if the ultimate goal is to
be placed in the body. When working with PCL-PEDOT based scaffolds, our results did not follow
those of the pure PCL. When printed at the previously determined ‘optimal’ parameters, the fibers
were immediately appeared as microfibers. Initially, it was believed that the introduction of the
conductive polymer would call for a smaller voltage, however, increasing the voltage helped
produce thin fibers as long as the distance was not too close to the collector. We thus determine
that optimal parameters for the MEW of PCL-PEDOT to be 8 kV at a speed of 50 mm/s and a
distance at 11 or 10 mm.

V.5. Future directions
This study on electrically conductive polymer composites is based on the idea that such
composites can be used to create a scaffold for cells to adhere and grow on, so that electrical
stimulation can be applied directly to them. This study serves as a first step to a much larger study
that may be used to study the ability to enhance bone regeneration and inhibit bacterial growth.
This study could also serve as a platform to study the effects of electrical stimulation on multiple
cell types including skin, nerve, and muscle cells. These in-vitro electrical stimulation studies
could lead to the development of a homemade electrical stimulation device. Current electrical
stimulation devices for in-vitro tests involve invasive implantation, which could lead to less
accurate observations. The development of a homemade device would look to overcome this, and
instead create something on the lines of capacitor plates, or inductive coils. This could further be
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created into a wireless stimulation device for in-vivo applications, furthering the use of electrical
stimulation as an effective stimulus for bone regeneration.

Investigation on PCL-PEDOT scaffolds is also important to continue including chemical,
mechanical, conductive, and osteogenic characterization. Understanding these features will lead
to have an impact on the scaffold fabrication parameters, as more in-depth focus is needed to create
appropriate scaffolds for bone. A PCL-PEDOT hybrid scaffold may prove to be an efficient
substrate for electrical stimulation, yet the use of PCL may not be the most appropriate polymer to
use for bone regeneration. This is mainly due to its degradation rate. Other polymers, such as polyl-lactic acid (PLLA) or polydioxanone (PDS), or copolymer combination so the two, may offer
greater efficacy in the regeneration of bone, due to their degradation rate and hydrophilicity. A
fully designed and studied electroactive scaffold could then be implanted in a rat nonunion model
study, to determine its ability to regenerate bone.
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CHAPTER V

CONCLUSIONS
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This study reports on the synthesis of a novel electrically conductive and biocompatible
biomaterial; the affect the biomaterial has on the cellular behaviors of BMSCs, and the fabrication
into a 3D conductive scaffold. From the study, the following conclusions were obtained.

Nanocomposites of PEDOT combined with DMSO and GO were successfully oxidatively
polymerized as indicated by the results of TEM-EDX, SEM-EDS, XPS, UV-Vis, and XRD studies.
The data provided by these studies showed that PEDOT could be polymerized in various solvents.
The PEDOTs showed their characteristic features for elemental and chemical composition, as well
as in their optical and crystallographic properties. This study demonstrated for the first time, that
the reaction yield for the polymerization of PEDOT can be enhanced by altering the solvent used
to disperse the components for oxidative polymerization. It is concluded that solvents containing
H2O result in higher yields of PEDOT when compared to the other solvents tested. It can also be
concluded that the use of different solvents influences the morphology of the different PEDOT
composites, as well as the particle size and elemental composition. XPS results also show that the
doping levels of PEDOT increase with the addition of DMSO and GO as secondary dopants.

BMSCs were cultured in various PEDOT types revealing that PEDOT does not have a
cytotoxic effect on the cells. This is seen when BMSCs are cultured in direct contact with the
PEDOT and when in PEDOT extract media. This shows that there are no harmful byproducts that
come from the polymerization process or the degradation of PEDOT. It can also be concluded that
PEDOT allows for BMSCs adhesion and proliferation over an extensive amount of time. This
study reveals that the different PEDOTs have the ability to properly function as an effective
biomaterial for regenerative medicine applications. Finally, 3D nanofibrous PCL and PCL[GO/DMSO-doped PEDOT] scaffolds were fabricated utilizing novel melt-electrowriting
technology. Parameters for both scaffolds were determined to by altering the voltage, speed of
collection, distance between nozzle and collector, nozzle size, processing temperature, and
pressure. Together, the interplay between these parameters yielded a starting point for future
studies involved in the fabrication of nanofibrous scaffolds. These findings highlight, for the first
time, the creation of a novel electrically conductive scaffold to be used in electrical stimulation for
bone regeneration.
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